Pharmaceutical compositions for oral administration containing sulfasalazine and / or sulfasalazine organic salts, methods of manufacture and uses

The development of sulfasalazine organic salts in pharmaceutical compositions with enhanced solubility and stability addresses the low bioavailability issue, improving therapeutic efficacy and compliance by reducing dose size and adverse effects.

JP7587647B2Active Publication Date: 2024-11-20MEDAC GESELLSCHAFT FUR KLINISCHE SPEZIALPRAPARATE MBH
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2023125343
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2017-11-23
Filing Date
2023-08-01
Publication Date
2024-11-20
Estimated Expiration
2038-11-23

AI Technical Summary

Technical Problem

Sulfasalazine exhibits low solubility and bioavailability, leading to low systemic absorption and high variability in pharmacokinetics, resulting in adverse events and poor patient compliance due to large doses and undesirable metabolite exposure.

Method used

Development of pharmaceutical compositions containing sulfasalazine organic salts, such as meglumine, piperazine, or diethylamine salts, with improved solubility and stability, formulated into oral dosage forms using enteric coatings and specific manufacturing methods to enhance bioavailability and reduce adverse effects.

Benefits of technology

The improved solubility and bioavailability of sulfasalazine salts result in reduced dose requirements, enhanced therapeutic efficacy, and better patient compliance by minimizing adverse events and metabolite exposure, while maintaining stability and effectiveness in treating inflammatory conditions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007587647000005
    Figure 0007587647000005
  • Figure 0007587647000006
    Figure 0007587647000006
  • Figure 0007587647000007
    Figure 0007587647000007
Patent Text Reader

Abstract

To provide a pharmaceutical composition of sulfasalazine with an increased bioavailability of sulfasalazine and / or solubility of sulfasalazine and / or an improved risk-benefit ratio of the pharmaceutical sulfasalazine composition, in particular for a decreased degree of adverse events and / or an improved patient compliance.SOLUTION: A pharmaceutical composition for oral administration comprises i) a core material and ii) an enteric coating material applied onto the core material as a layer. The i) core material comprises the following constituents: a) a therapeutically effective amount of 2-hydroxy-5-[2-[4-[(2-pyridinylamino)sulfonyl]phenyl]diazenyl]-benzoic acid (sulfasalazine) and / or a sulfasalazine organic salt; b) an organic amine-containing constituent selected from meglumine, piperazine and diethylamine; and c) one or more further pharmaceutical additives.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to novel pharmaceutical compositions for oral administration containing sulfasalazine and / or organic salts of sulfasalazine, methods of manufacture and uses, particularly in the treatment of diseases or conditions in which modulation of inflammatory cells is beneficial, diseases or conditions involving bone or joints and / or the digestive tract. [Background technology]

[0002] The compound known by the generic name sulfasalazine (also known as (3Z)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid (IUPAC); 2-hydroxy-5-[2-[4-[(2-pyridinylamino)sulfonyl]phenyl]diazenyl]-benzoic acid (CA index name)) was first disclosed in U.S. Pat. No. 2,396,145 (GB 564990) and is highly effective in treating various autoimmune diseases, such as rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, ulcerative colitis and Crohn's disease.

[0003] Sulfasalazine forms tan crystals (molecular weight 398.39 g / mol). The melting point has been determined to be 240°C-245°C (US 2,396,145). The solubility of sulfasalazine in water is less than 5 mg / 100 ml. The material has four theoretical pk values ​​of 0.6, 2.4, 9.7, and 11.8. a / b It has proven extremely difficult to prepare hydrate- and solvate-free salts of sulfasalazine using established methods.

[0004] The structure of sulfasalazine ((3Z)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid (IUPAC); 2-hydroxy-5-[2-[4-[(2-pyridinylamino)sulfonyl]phenyl]diazenyl]-benzoic acid (CA Index Name)) is shown below: [ka]

[0005] Sulfasalazine is a well-established active pharmaceutical ingredient used in anti-inflammatory therapy. It is used in the treatment of active rheumatoid arthritis, active juvenile idiopathic oligoarthritis, active juvenile idiopathic polyarthritis and spondyloarthropathy with peripheral arthritis in humans. Sulfasalazine is also used as a prodrug of 5-aminosalicylic acid in the treatment of inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis. In adults, sulfasalazine is generally administered orally in tablets at doses of 500 to 4000 mg / day, based on the tolerability of sulfasalazine and its efficacy.

[0006] Sulfasalazine is one of the most widely used disease-modifying antirheumatic drugs (DMARDs) and is also used in combination with glucocorticoids and / or in combination with other small molecule DMARDs, such as methotrexate and / or hydroxychloroquine and / or biologic DMARDs, such as TNF-α related biologics.

[0007] The mechanism of action of sulfasalazine and its metabolites 5-aminosalicylic acid and sulfapyridine is still partially unknown. Sulfasalazine and / or its metabolites have anti-inflammatory and immunomodulatory properties in vivo and in vitro in various (inflammatory) cell types, such as T cells, dendritic cells, macrophages, natural killer cells, epithelial cells, B cells and mast cells, through different biological "pathways". For example, it has been shown that sulfasalazine-treated dendritic cells are unable to stimulate T cells due to inhibition of the NF-kB pathway (Matasic R et al 2001, 42, 440-445). Sulfasalazine has also been shown to inhibit the binding of TNF-α to its receptor in 125I-TNF-α displacement studies. In addition, sulfasalazine, like methotrexate, has been shown to increase adenosine release by inhibiting AICAR transformylase, thereby reducing inflammation (P Gadangi, M Longaker, D Naime, RI Levin, PA Recht, MC Montesinos, MT Buckley, G Carlin and BN Cronstein; "The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites.", J Immunol March 1, 1996, 156 (5) 1937-1941).The well-established antioxidant effect of sulfasalazine, in conjunction with its inhibitory effect on neutrophil oxidative burst, has been shown to be exerted both by its scavenging effect on reactive oxygen and nitrogen species as well as by its metal chelating properties (Couto D1, Ribeiro D, Freitas M, Gomes A, Lima JL, Fernandes E., Redox Rep. 2010;15(6):259-67. doi: 10.1179 / 135100010X12826446921707, "Scavenging of reactive oxygen and nitrogen species by the prodrug sulfasalazine and its metabolites 5-aminosalicylic acid and sulfapyridine.").

[0008] However, due to the low solubility of sulfasalazine (0.03 mg / mL in deionized water at 24 °C) and the currently known pharmaceutical compositions of sulfasalazine, the systemic bioavailability of sulfasalazine in humans is low (approximately 15-20% of an oral dose is absorbed in the small intestine) and the intra- and inter-intestinal variability of pharmacokinetics is high (C max (The median time to absorption is 4-12 hours, with a median peak concentration of 6 hours.) Unabsorbed sulfasalazine is converted by the aza-reducing gut flora to 5-aminosalicylic acid (10-30% of systemic bioavailability) and sulfapyridine (approximately 60% of systemic bioavailability). Metabolites can be detected in plasma after approximately 10 hours. The half-life of intravenously administered sulfasalazine is approximately 7.6 ± 3.6 hours.

[0009] Apart from the biotransformation of sulfasalazine by the gut flora in the lower gastrointestinal tract, sulfasalazine is also metabolized in the liver to the metabolites 5-aminosalicylic acid and sulfapyridine. In the liver, the primary metabolite sulfapyridine is acetylated before excretion, the rate of which is determined by the acetylation phenotype. Thus, the half-life of sulfapyridine can vary from 10.4 to 14.8 hours (depending on the fast or rather slow acetylation phenotype).

[0010] The most common side effects associated with sulfasalazine are anorexia, headache, nausea, vomiting, stomach discomfort, although apparent reversible oligospermia, dizziness, fever, asthenia, insomnia and vertigo may also affect patients while taking sulfasalazine.

[0011] However, gastrointestinal reactions including hepatitis, liver failure, pancreatitis, bloody diarrhea, folate malabsorption, digoxin malabsorption, stomatitis, diarrhea, abdominal pain, and neutropenic enterocolitis may also occur during administration.

[0012] Also, the skin (e.g. skin rash or pruritus, hives, increased sensitivity to sunlight), blood / lymphatic system (aplastic anemia, agranulocytosis, leukopenia, megaloblastic (macrocytic) anemia, purpura, thrombocytopenia, thrombocytopenia, methemoglobinemia, congenital neutropenia and myelodysplastic syndromes) or central nervous system (transverse myelitis, convulsions, meningitis, posterior spinal transient lesions, cauda equina syndrome, Guillain-Barre syndrome, peripheral neuropathy, mental depression, vertigo, hearing loss, insomnia, ataxia, hallucinations, tinnitus and drowsiness). The hepatobiliary damage that occurs can be hepatotoxicity including elevated liver function tests (SGOT / AST, SGPT / ALT, GGT, LDH, alkaline phosphatase, bilirubin), jaundice, cholestatic jaundice, cirrhosis, cholestatic hepatitis, cholestasis and potentially hepatocellular injury including hepatic necrosis and liver failure. Some of these cases have been fatal.

[0013] The low absorption rate of sulfasalazine is one reason why large amounts of sulfasalazine, up to 500 mg per single solid oral dosage form, need to be administered to patients to obtain sufficient exposure to the drug sulfasalazine and thus sufficient clinical effect. However, large amounts of drug substance and / or large tablet size can result in poor patient compliance and unnecessarily high rates of adverse events, in part due to undesirable ratios of sulfasalazine and its metabolites in vivo.

[0014] In the manufacture of pharmaceutical compositions, it is important that the active compound is in a form that can be conveniently handled and processed to obtain a commercially viable manufacturing process.In this regard, the chemical and physical stability of the active compound are important factors.The active compound and the compositions containing it must be able to be effectively stored for a significant period of time without showing significant changes in physicochemical properties (e.g. chemical composition, density, moisture content and solubility).

[0015] Therefore, it would be beneficial to provide a solvate-free crystalline form of sulfasalazine that exhibits solubility.From the prior art, it is evident that it is extremely difficult to prepare and / or isolate solvate-free crystals of sulfasalazine while at the same time improving solubility.

[0016] It is known that sulfasalazine has metal chelating properties in vivo. However, the monosalts of sulfasalazine with counterions sodium and potassium have not yet been isolated, although they are mentioned in Nygard, B.; Olofsson, J. and Sandberg, M.: "Some physicochemical properties of salicylazosulphapyridine, including its solubility, protolytic constants and general spectrochemical and Polarographic behavior.", Acta Pharmaceutica Suecica 3: 313-342 (1966). The hemisalts of sulfasalazine with metal counterions such as strontium (as trihydrate), calcium (as trihydrate), and magnesium (as trihydrate) are less soluble than sulfasalazine. Other metal complexes of sulfasalazine with ammonium (cerium, thorium and uranium) have been similarly tested (GG Mohamed et al. Spectrochim Acta A Mol Biomol Spectrosc 62 (4-5), 1095-1101. 2005 Jun 13; "Structural and Thermal Characterization of Cerium, Thorium and Uranyl Complexes of Sulfasalazine").

[0017] Conformational analysis of sulfasalazine salts with various counterions such as Mg, Sr, Ca and Zn indicates that the terminal pyridine ring exhibits a degree of oriental flexibility, which indicates a propensity for conformational polymorphism of sulfasalazine salts.

[0018] Patent application GB 1,166,684 discloses alkoxy-amine addition salts of sulfasalazine. According to the patent, the prepared alkoxy-amine addition salts of sulfasalazine are difficult to crystallize in that they are obtained as viscous oils that crystallize only when stirred with ether or alcohol, and many of the disclosed salts are highly hygroscopic and / or have high water content. For example, N-methyl-(1)-D-glucosamine salt of sulfasalazine (also known as meglumine salt, as used below) is identified in GB 1,166,684 and is prepared by adding a solution of methylglucamine in hot methyl glycol to a solution of sulfasalazine in 2-methoxyethanol, and shows a water content of 9% after thorough drying. Such a water content is particularly unsuitable for the preparation of a stable pharmaceutical composition.

[0019] Due to their unfavourable physicochemical properties (hygroscopicity and / or high water content and / or low solubility and / or pharmaceutical unacceptability), the sulfasalazine salts disclosed thus far are not considered suitable for use in pharmaceutical compositions.

[0020] CN 106 279 008 A relates to the technical field of a method for purifying sulfasalazine (5-[p-(2-pyridylaminosulfonyl)benzene]azo-salicylic acid). Sulfasalazine is purified by using a specific amine salt of sulfasalazine as an intermediate product and precipitating sulfasalazine from a solution containing the specific amine salt. According to Example 6, a specific diethylamine salt of sulfasalazine is prepared as an intermediate product, and then sulfasalazine is precipitated from the solution. The applicant has prepared a sulfasalazine diethylamine salt intermediate according to the description provided in Example 6 of CN 106 279 008 A. The diethylamine salt of sulfasalazine was also evaluated by X-ray powder diffraction (XRPD), which demonstrated that the obtained diethylamine sulfasalazine exists as Form A crystals of the diethylamine salt of sulfasalazine according to FIG. 3.

[0021] Thus, there remains a need to provide pharmaceutical compositions of sulfasalazine that increase the bioavailability of sulfasalazine and / or the solubility of sulfasalazine, and / or improve the risk-benefit ratio of pharmaceutical sulfasalazine compositions, particularly to reduce the severity of adverse events and / or improve patient compliance. Summary of the Invention

[0022] The object of the present invention is achieved by the subject matter of the independent claims. Advantages (preferred embodiments) are shown in the following detailed description including the drawings and in the dependent claims.

[0023] Accordingly, a first aspect of the present invention is a method for preparing a pharmaceutical composition for oral administration comprising 2-hydroxy-5-[2-[4-[(2-pyridinylamino)sulfonyl]phenyl]diazenyl]-benzoic acid (sulfasalazine) and / or a sulfasalazine organic salt, comprising the steps of: A: providing sulfasalazine; B: providing an organic amine-containing component, preferably selected from meglumine, piperazine and diethylamine; C: Providing one or more pharmaceutical excipients and optionally one or more further active ingredients; D: mixing a therapeutically effective amount of sulfasalazine of step A) with a suitable amount of the organic amine-containing component of step B) and one or more pharmaceutical excipients and optionally one or more additional active ingredients of step C) to form a pharmaceutical composition for oral administration; comprising or consisting of The method of manufacture relates to wherein the organic amine-containing component is not tris(hydroxymethyl)aminomethane (tromethane base).

[0024] A second aspect of the present invention relates to a pharmaceutical composition for oral administration obtainable according to the process of the present invention.

[0025] A third aspect of the present invention is i) a human disease or condition in which modulation of inflammatory cells is beneficial; ii) diseases or conditions relating to bone or joints, preferably arthritis associated with or including osteoarthritis, primary or secondary to, for example, congenital hip dysplasia; cervical and lumbar spondylitis, and lower back and neck pain; rheumatoid arthritis and Still's disease; seronegative spondyloarthropathy, such as ankylosing spondylitis, psoriatic arthritis, reactive arthritis and undifferentiated spondarthropathy, septic arthritis and other arthopathies and bone disorders associated with infections, such as tuberculosis, e.g. Pott's disease and Ponce's disease; acute and chronic crystal-induced synovitis, such as urate gout, calcium pyrophosphate deposition disease, and calcium apatite associated tendonitis. tendon), bursal and synovial inflammation; Behcet's disease; primary or secondary Sjogren's syndrome; systemic sclerosis and localized scleroderma; systemic lupus erythematosus, mixed connective tissue disease, and undifferentiated connective tissue disease; inflammatory myopathies, such as dermatomyositis and polymyositis; polymyalgia rheumatica; juvenile arthritis, such as idiopathic inflammatory arthritis of any joint location and associated syndrome, and rheumatic fever and its systemic complications; vasculitis, such as giant cell arteritis, Takayasu's arteritis, Churg-Strauss syndrome, polyarteritis nodosa, microscopic polyarteritis, and vasculitis associated with viral infections, hypersensitivity reactions, cryoglobulins, and paraproteins; lower back pain; Familial Mediterranean Fever, Muckle-Wells syndrome, and Familial Hibernian Fever, Kikuchi's disease; a disease or condition selected from the group consisting of drug-induced joint pain, tendonitis, and myopathy; and iii) diseases or conditions relating to the digestive tract, preferably selected from the group consisting of eosinophilic gastroenteritis, mastocytosis, Crohn's disease, colitis, e.g. ulcerative colitis, proctitis; celiac disease, irritable bowel syndrome, and food-related allergies that may affect areas distant from the intestine, e.g. migraine, rhinitis or eczema. The present invention relates to a pharmaceutical composition of the present invention for use in the treatment of

[0026] A fourth aspect of the present invention is i) a human disease or condition in which modulation of inflammatory cells is beneficial; ii) diseases or conditions relating to bone or joints, preferably arthritis associated with or including osteoarthritis, primary or secondary to, for example, congenital hip dysplasia; cervical and lumbar spondylitis, and lower back and neck pain; rheumatoid arthritis and Still's disease; seronegative spondyloarthropathy, such as ankylosing spondylitis, psoriatic arthritis, reactive arthritis and undifferentiated spondarthropathy, septic arthritis and other arthopathies and bone disorders associated with infections, such as tuberculosis, e.g. Pott's disease and Ponce's disease; acute and chronic crystal-induced synovitis, such as urate gout, calcium pyrophosphate deposition disease, and calcium apatite associated tendonitis. tendon), bursal and synovial inflammation; Behcet's disease; primary or secondary Sjogren's syndrome; systemic sclerosis and localized scleroderma; systemic lupus erythematosus, mixed connective tissue disease, and undifferentiated connective tissue disease; inflammatory myopathies, such as dermatomyositis and polymyositis; polymyalgia rheumatica; juvenile arthritis, such as idiopathic inflammatory arthritis of any joint location and associated syndrome, and rheumatic fever and its systemic complications; vasculitis, such as giant cell arteritis, Takayasu's arteritis, Churg-Strauss syndrome, polyarteritis nodosa, microscopic polyarteritis, and vasculitis associated with viral infections, hypersensitivity reactions, cryoglobulins, and paraproteins; lower back pain; Familial Mediterranean Fever, Muckle-Wells syndrome, and Familial Hibernian Fever, Kikuchi's disease; a disease or condition selected from the group consisting of drug-induced joint pain, tendonitis, and myopathy; and iii) diseases or conditions relating to the digestive tract, preferably selected from the group consisting of eosinophilic gastroenteritis, mastocytosis, Crohn's disease, colitis, e.g. ulcerative colitis, proctitis; celiac disease, irritable bowel syndrome, and food-related allergies that may affect areas distant from the intestine, e.g. migraine, rhinitis or eczema. The present invention relates to the use of a pharmaceutical composition of the present invention in the manufacture of a medicament for / in the treatment of

[0027] A fifth aspect of the present invention is i) a human disease or condition in which modulation of inflammatory cells is beneficial; ii) diseases or conditions relating to bone or joints, preferably arthritis associated with or including osteoarthritis, primary or secondary to, for example, congenital hip dysplasia; cervical and lumbar spondylitis, and lower back and neck pain; rheumatoid arthritis and Still's disease; seronegative spondyloarthropathy, such as ankylosing spondylitis, psoriatic arthritis, reactive arthritis and undifferentiated spondarthropathy, septic arthritis and other arthopathies and bone disorders associated with infections, such as tuberculosis, e.g. Pott's disease and Ponce's disease; acute and chronic crystal-induced synovitis, such as urate gout, calcium pyrophosphate deposition disease, and calcium apatite associated tendonitis. tendon), bursal and synovial inflammation; Behcet's disease; primary or secondary Sjogren's syndrome; systemic sclerosis and localized scleroderma; systemic lupus erythematosus, mixed connective tissue disease, and undifferentiated connective tissue disease; inflammatory myopathies, such as dermatomyositis and polymyositis; polymyalgia rheumatica; juvenile arthritis, such as idiopathic inflammatory arthritis of any joint location and associated syndrome, and rheumatic fever and its systemic complications; vasculitis, such as giant cell arteritis, Takayasu's arteritis, Churg-Strauss syndrome, polyarteritis nodosa, microscopic polyarteritis, and vasculitis associated with viral infections, hypersensitivity reactions, cryoglobulins, and paraproteins; lower back pain; Familial Mediterranean Fever, Muckle-Wells syndrome, and Familial Hibernian Fever, Kikuchi's disease; a disease or condition selected from the group consisting of drug-induced joint pain, tendonitis, and myopathy; and iii) diseases or conditions relating to the digestive tract, preferably selected from the group consisting of eosinophilic gastroenteritis, mastocytosis, Crohn's disease, colitis, e.g. ulcerative colitis, proctitis; celiac disease, irritable bowel syndrome, and food-related allergies that may affect areas distant from the intestine, e.g. migraine, rhinitis or eczema. The present invention relates to a method of treating a disease or condition in a patient suffering from or at risk of said disease or condition, comprising administering to the patient a pharmaceutical composition of the present invention.

[0028] A sixth aspect of the invention relates to a pharmaceutical composition according to the invention, wherein the pharmaceutical composition according to the invention is co-administered sequentially or in parallel with one or more further pharmaceutical compositions, wherein the one or more active ingredients are preferably non-steroidal anti-inflammatory drugs; preferably non-selective cyclo-oxygenase COX-1 / COX-2 inhibitors, whether applied locally or systemically, such as piroxicam, diclofenac, propionic acids, such as naproxen, flurbiprofen, fenoprofen, ketoprofen and ibuprofen, fenamates, such as mefenamic acid, indomethacin, sulindac, azapropazones, pyrazolones, such as phenylbutazone, salicylates, such as aspirin, selective COX-2 inhibitors, such as meloxicam, celecoxib, rofecoxib, valdecoxib, lumiracoxib. , parecoxib and etoricoxib, cyclooxygenase inhibitors that donate nitric oxide (CINOD); glucocorticoids, preferably flunisolide, triamcinolone acetonide, betamethasone dipropionate, budesonide, fluticasone propionate, ciclesonide or mometasone furoate; methotrexate; leflunomide; hydroxychloroquine; d-penicillamine; diacerein; dietary supplements, preferably glucosamine; gold preparations, preferably auranofin; cytokines or agonists or antagonists of cytokine function; monoclonal antibodies targeting B lymphocytes, preferably CD20 (rituximab); MRA-aIL16R; T-lymphocytes; CTLA4-Ig; HuMax 11-15; modulators of chemokine receptor function, preferably antagonists of CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCRlO and CCR11 (CC family), CXCRl, CXCR2, CXCR3, CXCR4 and CXCR5 (CXC family) and CX3CR1 (C-X3-C family); azathioprine, tofacitinib, monoclonal antibodies such as the anti-tumor necrosis factor alpha monoclonal antibodies infliximab, adalimumab and golimumab; interleukin 1 receptor antagonists such as anakinra; etanercept and abatacept;The pharmaceutical composition of the invention, the use of the pharmaceutical composition of the invention and the method of treating a patient of the invention are characterized in that the compound is more preferably selected from the group consisting of methotrexate and hydroxychloroquine;

[0029] The present invention also includes the following aspects and embodiments. [1] A method for preparing a pharmaceutical composition for oral administration comprising 2-hydroxy-5-[2-[4-[(2-pyridinylamino)sulfonyl]phenyl]diazenyl]-benzoic acid (sulfasalazine) and / or sulfasalazine as an organic salt, comprising the steps of: A: providing sulfasalazine; B: providing an organic amine-containing component, preferably selected from meglumine, piperazine and diethylamine; C: Providing one or more pharmaceutical excipients and optionally one or more further active ingredients; D: mixing a therapeutically effective amount of sulfasalazine of step A) with a suitable amount of the organic amine-containing component of step B) and one or more pharmaceutical excipients and optionally one or more additional active ingredients of step C) to form a pharmaceutical composition for oral administration; comprising or consisting of A manufacturing method in which the organic amine-containing component is not tris(hydroxymethyl)aminomethane. [2] In step D), a core material is formed comprising sulfasalazine and / or an organic sulfasalazine amine salt, the method further comprising or consisting of applying one or more coating layers to the core material to form a pharmaceutical composition for oral administration, the method comprising the steps of: E: Optionally, coating the core material produced in step D) with one or more separating layers, preferably selected from pH buffers; F: Coating the core material produced in step D) or the core material comprising one or more separating layers produced in step E) with an enteric coating; G: Optionally, coating the enteric coated core material of step F) with an overcoating layer; and H: Optionally, formulating the enteric coated core material of step F) or the enteric coated and overcoated core material of step G) into a tablet or capsule. The method according to [1], further comprising or consisting of: [3] The method according to [2], characterized in that the core material of step D) or the core material comprising one or more separating layers of step E) is compressed to form a tablet before coating the compressed core material with an enteric coating in step F). [4] The method according to [2] or [3], wherein the thickness of the enteric coating layer is at least 5 μm, more preferably at least 10 μm. [5] The capsules in step H) i. as a soft gelatin capsule, preferably with one or more further pharmaceutical excipients selected from the group consisting of surfactants / solubilizers, preferably tocopheryl polyethylene glycol succinate (TPGS), vegetable oils and / or polyethylene glycol; ii. As a hard gelatin capsule, with one or more additional pharmaceutical additives selected from the group consisting of surfactants / solubilizers, preferably tocopheryl polyethylene glycol succinate (TPGS). The method according to any one of [2] to [4], wherein a metal oxide film is formed. [6] In step D), the core material is D1: A method selected from the group consisting of wet extrusion, wet spheronization, hot melt extrusion, hot melt pelletization, fluidized bed spray encapsulation, balling, and compression. The method according to any one of [2] to [5], wherein the production is carried out by [7] The one or more pharmaceutical additives in step C) comprise or consist of seed materials as excipients, in particular water-insoluble seed materials, preferably selected from the group consisting of oxidized materials, cellulose materials, organic polymeric materials or mixtures thereof, and / or water-soluble seed materials, such as nonpareils, preferably selected from the group consisting of inorganic salt materials, sugar materials, starch materials or mixtures thereof, and in step D) the core material is D2: Prepared by coating the seed material provided in step C) with the sulfasalazine provided in step A) and the organic amine component provided in step B) and, optionally, further with pharmaceutical additives provided in step C), preferably selected from the group consisting of binders, surfactants, excipients, lubricants, disintegrants, alkaline additives and buffers, the coating being preferably prepared by powder or solution layering, more preferably spray drying or spray congealing. The method according to any one of [2] to [6], [8] The method according to any one of [1] to [7], wherein the produced pharmaceutical composition for oral administration is a solid pharmaceutical composition, preferably selected from the group consisting of granules, preferably multi-unit pellet systems (MUPS), tablets, preferably multi-unit pellet tablets (MUP tablets), capsules and powders; or a liquid pharmaceutical composition, preferably selected from the group consisting of syrups and suspensions. [9] The sulfasalazine in the prepared pharmaceutical composition for oral administration is preferably i. crystalline meglumines sulfasalazine Form A characterized by powder X-ray diffraction peaks at 2θ values ​​of 6.35, 13.93, 15.48, 15.86, 20.99, 22.41, 23.60 and 28.07 (±0.2), preferably having an X-ray powder diffraction pattern substantially identical to that shown in FIG. 1; and / or ii. crystalline piperazine sulfasalazine Form A characterized by powder X-ray diffraction peaks at 2θ values ​​of 12.3, 12.93, 15.0, 16.42, 22.41 and 23.4 (±0.2), preferably having an X-ray powder diffraction pattern substantially identical to that shown in FIG. 2; and / or iii. crystalline diethylamine sulfasalazine Form A characterized by powder X-ray diffraction peaks at 2θ values ​​of 7.16, 10.50, 11.48, 18.78, 21.65 and 21.87 (±0.2), preferably having a powder X-ray diffraction pattern substantially identical to that shown in FIG. 3; and / or iv. Diethylamine sulfasalazine Form B crystals characterized by powder X-ray diffraction peaks at 2θ values ​​(±0.2) of 6.85, 11.38, 11.70, 17.62, 20.58, 22.75 and 23.98, preferably diethylamine sulfasalazine Form B crystals having a powder X-ray diffraction pattern substantially identical to that shown in FIG. 4. The method according to any one of [1] to [8], characterized in that the method comprises or consists of an organic sulfasalazine salt selected from the group consisting of:

[10] The therapeutically effective amount of sulfasalazine per dose of the pharmaceutical composition for oral administration is in the range of 10 mg to 2,000 mg, preferably 10 mg, 20 mg, 25 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 75 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg, 125 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 175 mg, 180 mg, 190 mg, 200 mg, 210 mg, 220 mg, 225 mg, 230 mg, 240 mg, 250 mg, 260 mg, 270 mg, 275 mg, 280 mg, 290 mg, 300 mg, 310 mg, 320 mg, 325 mg, 330 mg, 340 mg, 350 mg, 360 mg, 370 mg, 375 mg, 380 mg, 390 mg, 400 mg, 410 mg, 420 mg, 430 mg, 440 mg, 450 mg, 460 mg, 470 mg, 480 mg, 490 mg, 500 mg, 510 mg, 520 mg, 530 mg, 540 mg, 550 mg, 560 mg, 570 mg, 580 mg, 590 mg, 600 mg, 610 mg, 620 mg, 630 mg, 640 mg, 650 mg, 660 mg, 670 mg, 680 mg, 690 mg, 700 mg, 710 mg, 720 mg, 730 mg, 380 mg, 390 mg, 400 mg, 410 mg, 420 mg, 425 mg, 430 mg, 440 mg, 450 mg, 460 mg, 470 mg, 475 mg, 480 mg, 490 mg, 500 mg, 525 mg, 550 mg, 575 mg, 600 mg, 625 mg, 650 mg, 675 mg, 700 mg, 725 mg, 750 mg, 775 mg, 800 mg, 825 mg, 850 mg, 875 mg, 900 mg, 925 mg, 950 mg, 975 mg, 1,000 mg, 1,025 mg, 1,050 mg, 1,075 mg, 1,100 mg, 1,125 mg, 1,150 mg, 1,175 mg, 1,200 mg, 1,225 mg, 1,250 mg, 1,275 mg, 1,300 mg, 1,325 mg, 1,350 mg, 1,375 mg, 1,400 mg, 1,425 mg, 1,450 mg, 1,475 mg, 1,500 mg, 1,525 mg, 1,550 mg, 1,575 mg, 1,600 mg, 1,625 mg, 1,650 mg, 1,675 mg, 1,700 mg, 1,725 ​​mg, 1,750 mg, 1,775 mg, 1,800 mg, 1,825 mg, 1,850 mg, 1,875 mg, 1,900 mg, 1,925 mg, 1,950 mg, 1,975 mg, 2,The method for producing the present invention according to any one of [1] to [9], wherein the amount of the active ingredient is 1,000 mg.

[11] A pharmaceutical composition for oral administration, obtained according to any one of claims 1 to 10.

[12] i) a human disease or condition in which modulation of inflammatory cells is beneficial; ii) diseases or conditions relating to bones or joints, preferably arthritis associated with or including osteoarthritis, primary or secondary to, for example, congenital hip dysplasia; cervical and lumbar spondylitis, and lower back and neck pain; rheumatoid arthritis and Still's disease; seronegative spondyloarthropathy, such as ankylosing spondylitis, psoriatic arthritis, reactive arthritis and undifferentiated spondyloarthropathy, septic arthritis and other arthropathies and bone disorders associated with infections, such as tuberculosis, e.g. Pott's disease and Ponce's disease; acute and chronic crystal-induced synovitis, such as uric acid gout, calcium pyrophosphate deposition disease, and calcium apatite-associated tendon, bursa and synovial inflammation; Behcet's disease; primary or secondary Sjogren's syndrome; systemic sclerosis and localized forms. scleroderma; systemic lupus erythematosus, mixed connective tissue disease, and undifferentiated connective tissue disease; inflammatory myopathies, such as dermatomyositis and polymyositis; polymyalgia rheumatica; juvenile arthritis, such as idiopathic inflammatory arthritis of any joint location and associated syndromes, and rheumatic fever and its systemic complications; vasculitis, such as giant cell arteritis, Takayasu's arteritis, Churg-Strauss syndrome, polyarteritis nodosa, microscopic polyarteritis, and vasculitis associated with viral infections, hypersensitivity reactions, cryoglobulins, and paraproteins; lower back pain; familial Mediterranean fever, Muckle-Wells syndrome, and familial Irish fever, Kikuchi's disease; a disease or condition selected from the group consisting of drug-induced arthralgia, tendonitis, and myopathy; and iii) diseases or conditions relating to the digestive tract, preferably selected from the group consisting of eosinophilic gastroenteritis, mastocytosis, Crohn's disease, colitis, e.g. ulcerative colitis, proctitis; celiac disease, irritable bowel syndrome, and food-related allergies that may affect areas distant from the intestine, e.g. migraine, rhinitis or eczema. The pharmaceutical composition according to

[11] for use in the treatment of.

[13] i) a human disease or condition in which modulation of inflammatory cells is beneficial; ii) diseases or conditions relating to bones or joints, preferably arthritis associated with or including osteoarthritis, primary or secondary to, for example, congenital hip dysplasia; cervical and lumbar spondylitis, and lower back and neck pain; rheumatoid arthritis and Still's disease; seronegative spondyloarthropathy, such as ankylosing spondylitis, psoriatic arthritis, reactive arthritis and undifferentiated spondyloarthropathy, septic arthritis and other arthropathies and bone disorders associated with infections, such as tuberculosis, e.g. Pott's disease and Ponce's disease; acute and chronic crystal-induced synovitis, such as uric acid gout, calcium pyrophosphate deposition disease, and calcium apatite-associated tendon, bursa and synovial inflammation; Behcet's disease; primary or secondary Sjogren's syndrome; systemic sclerosis and localized forms. scleroderma; systemic lupus erythematosus, mixed connective tissue disease, and undifferentiated connective tissue disease; inflammatory myopathies, such as dermatomyositis and polymyositis; polymyalgia rheumatica; juvenile arthritis, such as idiopathic inflammatory arthritis of any joint location and associated syndromes, and rheumatic fever and its systemic complications; vasculitis, such as giant cell arteritis, Takayasu's arteritis, Churg-Strauss syndrome, polyarteritis nodosa, microscopic polyarteritis, and vasculitis associated with viral infections, hypersensitivity reactions, cryoglobulins, and paraproteins; lower back pain; familial Mediterranean fever, Muckle-Wells syndrome, and familial Irish fever, Kikuchi's disease; a disease or condition selected from the group consisting of drug-induced arthralgia, tendonitis, and myopathy; and iii) diseases or conditions relating to the digestive tract, preferably selected from the group consisting of eosinophilic gastroenteritis, mastocytosis, Crohn's disease, colitis, e.g. ulcerative colitis, proctitis; celiac disease, irritable bowel syndrome, and food-related allergies that may affect areas distant from the intestine, e.g. migraine, rhinitis or eczema. Use of the pharmaceutical composition described in

[11] in the manufacture of a medicament for / in the treatment thereof.

[14] i) a human disease or condition in which modulation of inflammatory cells is beneficial; ii) diseases or conditions relating to bones or joints, preferably arthritis associated with or including osteoarthritis, primary or secondary to, for example, congenital hip dysplasia; cervical and lumbar spondylitis, and lower back and neck pain; rheumatoid arthritis and Still's disease; seronegative spondyloarthropathy, such as ankylosing spondylitis, psoriatic arthritis, reactive arthritis and undifferentiated spondyloarthropathy, septic arthritis and other arthropathies and bone disorders associated with infections, such as tuberculosis, e.g. Pott's disease and Ponce's disease; acute and chronic crystal-induced synovitis, such as uric acid gout, calcium pyrophosphate deposition disease, and calcium apatite-associated tendon, bursa and synovial inflammation; Behcet's disease; primary or secondary Sjogren's syndrome; systemic sclerosis and localized forms. scleroderma; systemic lupus erythematosus, mixed connective tissue disease, and undifferentiated connective tissue disease; inflammatory myopathies, such as dermatomyositis and polymyositis; polymyalgia rheumatica; juvenile arthritis, such as idiopathic inflammatory arthritis of any joint location and associated syndromes, and rheumatic fever and its systemic complications; vasculitis, such as giant cell arteritis, Takayasu's arteritis, Churg-Strauss syndrome, polyarteritis nodosa, microscopic polyarteritis, and vasculitis associated with viral infections, hypersensitivity reactions, cryoglobulins, and paraproteins; lower back pain; familial Mediterranean fever, Muckle-Wells syndrome, and familial Irish fever, Kikuchi's disease; a disease or condition selected from the group consisting of drug-induced arthralgia, tendonitis, and myopathy; and iii) diseases or conditions relating to the digestive tract, preferably selected from the group consisting of eosinophilic gastroenteritis, mastocytosis, Crohn's disease, colitis, e.g. ulcerative colitis, proctitis; celiac disease, irritable bowel syndrome, and food-related allergies that may affect areas distant from the intestine, e.g. migraine, rhinitis or eczema. A method for treating a disease or condition in a patient suffering from or at risk of having the disease or condition, the method comprising administering to the patient the pharmaceutical composition described in

[11] .

[15] The pharmaceutical composition according to

[11] may be co-administered sequentially or in parallel with one or more further pharmaceutical compositions, the active ingredient(s) of which are preferably non-steroidal anti-inflammatory drugs; preferably non-selective cyclo-oxygenase COX-1 / COX-2 inhibitors, whether applied locally or systemically, such as piroxicam, diclofenac, propionic acids, such as naproxen, flurbiprofen, fenoprofen, ketoprofen and ibuprofen, fenamates, such as mefenamic acid, indomethacin, sulindac, azapropazones, pyrazolones, such as phenylbutazone, salicylates, such as aspirin, selective COX-2 inhibitors, such as meloxicam, celecoxib, rofecoxib, valdecoxib, lumiracoxib, valdec ... sib, parecoxib and etoricoxib, cyclooxygenase inhibitors that donate nitric oxide (CINOD); glucocorticoids, preferably flunisolide, triamcinolone acetonide, betamethasone dipropionate, budesonide, fluticasone propionate, ciclesonide or mometasone furoate; methotrexate; leflunomide; hydroxychloroquine; d-penicillamine; diacerein; dietary supplements, preferably glucosamine; gold preparations, preferably auranofin; cytokines or agonists or antagonists of cytokine function; monoclonal antibodies targeting B lymphocytes, preferably CD20 (rituximab); MRA-aIL16R; T-lymphocytes; CTLA4-Ig; HuMax 11-15; modulators of chemokine receptor function, preferably antagonists of CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCRlO and CCR11 (CC family), CXCRl, CXCR2, CXCR3, CXCR4 and CXCR5 (CXC family) and CX3CR1 (C-X3-C family); azathioprine, tofacitinib, monoclonal antibodies such as the anti-tumor necrosis factor alpha monoclonal antibodies infliximab, adalimumab and golimumab; interleukin 1 receptor antagonists such as anakinra; etanercept and abatacept;The pharmaceutical composition according to

[11] or

[12] , the use of the pharmaceutical composition according to

[13] , and the method for treating a patient according to

[14] , characterized in that the compound is more preferably selected from the group consisting of methotrexate and hydroxychloroquine; The aspects of the invention described below may also include any possible combination of the preferred embodiments described in the dependent claims or disclosed in the following detailed description, as would be reasonable to one skilled in the art. [Brief description of the drawings]

[0030] [Figure 1] 1 shows a powder X-ray diffraction pattern of crystalline Form A of the meglumine salt of sulfasalazine. [Diagram 2] 1 shows a powder X-ray diffraction pattern of crystalline Form A of the piperazine salt of sulfasalazine. [Diagram 3] 1 shows a powder X-ray diffraction pattern of crystalline Form A of the diethylamine salt of sulfasalazine. [Figure 4] 1 shows a powder X-ray diffraction pattern of crystalline Form B of the diethylamine salt of sulfasalazine. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0031] The inventors of the present application have demonstrated that the free acid form of sulfasalazine has poor gastrointestinal absorption (see Arik Dahan, Gordon L. Amidon; "Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting"; American Journal of Physiology - Gastrointestinal and Liver Physiology Published 21 July 2009 Vol. 297 no. 2, G371-G377) and poor permeability through Caco-2 cell monolayers (Liang E, Chessic K, Yazdanian M.; "Evaluation of an accelerated Caco-2 cell permeability model."; J Pharm Sci. 2000 Mar;89(3):336-45) compound, pharmaceutical compositions of sulfasalazine of the present invention have instead been found to exhibit improved permeability across Caco-2 cell monolayers compared to the free acid form of sulfasalazine (see Example 3, Table 3 below).

[0032] Also, the free acid form of sulfasalazine is classified as practically insoluble (<0.1 mg / mL) according to the United States Pharmacopeia, with a solubility of 0.031 mg / mL in deionized water at 24° C. According to measurements performed by the present inventors, the free acid form of sulfasalazine exhibits a solubility of 0.06 mg / mL in deionized water at 24° C., while sulfasalazine applied as the pharmaceutical composition of the present invention generally exhibits an increased solubility of ≧0.1 mg / mL, more preferably ≧0.5 mg / mL, ≧1 mg / mL in deionized water at 24° C. (see Example 1, Table 1 below).

[0033] Thus, due to increased bioavailability and / or solubility, reduced doses of sulfasalazine may be used in the therapeutic treatment of diseases or conditions where modulation of inflammatory cells is beneficial, such as rheumatoid arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis, where systemic exposure to sulfasalazine is necessary, without changing the total systemic exposure to sulfasalazine. This results in an improved risk-benefit profile, as it reduces exposure to sulfapyridine, a metabolite that is a common cause of some of the adverse events seen in patients treated with sulfasalazine (adverse events exemplified in the Background section of this application). In particular, patients with slow acetylation will benefit from reduced exposure to sulfapyridine. Furthermore, compliance with treatment may be improved due to the reduced burden of treatment through the use of fewer and / or smaller solid pharmaceutical compositions (e.g. tablets, microtablets, capsules, multi-unit pellet systems, etc.).

[0034] Furthermore, the inventive method for producing the inventive sulfasalazine pharmaceutical oral administration composition is stable (see Example 2, Table 2 below). The term "stable" in the context of the present invention means that the measured values ​​fall within a specific range of values ​​as determined according to the respective applicable regulatory guidelines, e.g., the European Pharmacopoeia.

[0035] The properties or physical and chemical stability of the pharmaceutical tablet compositions of the invention may be tested in a conventional manner, for example by measuring the appearance, hardness (or crush resistance), disintegration time, dissolution, friability, moisture content, quantification of the sulfasalazine salt of the invention and / or its degradation products (related substances), and / or uniformity of dosage units or masses after storage under controlled storage conditions, such as intermediate and / or accelerated conditions according to ICH guideline Q1A(R2) (i.e., 25° C. / 60% relative humidity (RH) and / or 40° C. / 75% RH). These tests are performed in accordance with applicable pharmaceutical regulatory standards, for example as described in ICH or EMA guidelines and / or the European Pharmacopoeia (EP).

[0036] At least some of these attributes, i.e. properties or physical and chemical stability, of the pharmaceutical tablet composition of the present invention, preferably most of these attributes, most preferably all of these attributes are stable over time and over various controlled storage conditions. According to a preferred embodiment, the dissolution (profile) of the pharmaceutical tablet composition of the present invention, e.g. tablets or film-coated tablets according to the present invention, is stable for at least 6 months when stored at intermediate or long-term storage conditions, i.e. 25°C / 60% RH or 40°C / 75% RH, preferably in Alu-Alu blisters. More preferably, the dissolution and further attributes, e.g. quantification, related substances or dosage unit or mass uniformity, are also stable after storage for at least 6 months when stored at intermediate or long-term storage conditions.

[0037] According to a first aspect of the present invention, there is provided an inventive process for the preparation of a pharmaceutical composition for oral administration comprising 2-hydroxy-5-[2-[4-[(2-pyridinylamino)sulfonyl]phenyl]diazenyl]-benzoic acid (sulfasalazine) in free acid form and / or as a sulfasalazine organic salt.

[0038] According to step A) of the manufacturing method of the present invention for obtaining the pharmaceutical composition of the present invention, a suitable amount of sulfasalazine is provided. According to all aspects of the present invention, sulfasalazine may be provided as a free acid form. Additionally or alternatively, sulfasalazine may also be provided in a salt form, preferably an organic salt form, such as an organic amine salt form, preferably as Form A crystals of D(-)-N-methylglucamine (meglumine) salt of sulfasalazine, Form A crystals of piperazine salt of sulfasalazine, Form A crystals of diethylamine salt of sulfasalazine and Form B crystals of diethylamine salt of sulfasalazine. The suitable amount of sulfasalazine is preferably selected so that the manufactured pharmaceutical composition of the present invention contains 0.01-100% by weight, 1-90% by weight, 25-80% by weight, 30-70% by weight, 40-60% by weight or 50% by weight of sulfasalazine, respectively, based on the total weight of the pharmaceutical composition of the present invention.

[0039] In accordance with the present invention, the phrase "crystalline Form A of the D(-)-N-methylglucamine salt of sulfasalazine" may be used synonymously with "crystalline Form A of the meglumine salt of sulfasalazine," "meglumine salt Form A," "meglumine sulfasalazine Form A" or "sulfasalazine meglumine salt."

[0040] In accordance with the present invention, the phrase "crystalline Form A of the piperazine salt of sulfasalazine" may be used synonymously with "crystalline Form A of the piperazine salt of sulfasalazine," "piperazine salt Form A," "piperazine sulfasalazine Form A," or "sulfasalazine piperazine salt."

[0041] In accordance with the present invention, the phrase "crystalline Form A of the diethylamine salt of sulfasalazine" may be used synonymously with "crystalline Form A of the diethylamine salt of sulfasalazine," "diethylamine salt Form A," or "diethylamine sulfasalazine Form A." In accordance with an optional alternative embodiment of the present invention, crystalline Form A of the diethylamine salt of sulfasalazine is not included in all aspects of the present invention, particularly the pharmaceutical compositions of the present invention.

[0042] In accordance with the present invention, the phrase "crystalline Form B of the diethylamine salt of sulfasalazine" may be used synonymously with "crystalline Form B of the diethylamine salt of sulfasalazine," "diethylamine salt Form B," or "diethylamine sulfasalazine Form B." In accordance with an optional alternative embodiment of the present invention, crystalline Form B of the diethylamine salt of sulfasalazine is not included in all aspects of the present invention, particularly the pharmaceutical compositions of the present invention.

[0043] According to yet another optional alternative embodiment of the present invention, the pharmaceutical composition of the present invention does not comprise a diethylamine salt of sulfasalazine.

[0044] According to one embodiment of all aspects of the invention, the sulfasalazine salt crystals are preferably at least 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% crystalline by weight, based on the total weight of the respective sulfasalazine salt form. Crystallinity may be estimated by conventional X-ray diffraction techniques.

[0045] According to a further embodiment of all aspects of the present invention, crystalline Form A of the meglumine salt of sulfasalazine exhibits at least the following characteristic powder X-ray diffraction (XPRD) peaks (expressed in 2θ°±0.2°) (in accordance with United States Pharmacopeia Convention. X-Ray Diffraction, General Test (USP941)): <941> United States Pharmacopeia, 25 th ed. Rockville, MD: United States Pharmacopeial Convention; 2002: 2088-2089): (1) 6.35, 13.93, and 22.41, or (2) 9.31, 15.86 and 20.99, or (3) 6.35, 13.93, 15.48, 15.86, 22.41, and 23.60; or (4) 6.35, 10.79, 12.93, 13.93, 15.48, 15.86, 18.12, 19.82, and 22.41; or (5) 9.31, 10.79, 12.93, 13.93, 14.47, 15.48, 15.86, 17.56, 19.10, 23.60, and 28.07; or (6) 6.35, 12.93, 13.93, 14.47, 15.48, 15.86, 19.10, 19.82, 20.99, 21.27, 22.41, 23.60, 23.89, and 28.07; or (7) 6.35, 9.31, 10.79, 12.93, 13.93, 14.47, 15.48, 15.86, 17.78, 18.12, 19.82, 20.11, 20.99, 21.27, 22.41, 23.60, 23.89, 28.07, and 28.80; or (8) 6.35, 9.31, 10.79, 12.93, 13.93, 14.47, 15.48, 15.86, 17.56, 17.78, 18.12, 18.50, 19.10, 19.82, 20.11, 20.99, 21.27, 22.41, 23.60, 23.89, 24.70, 25.14, 25.55, 25.93, 26.81, 28.07, and 28.80; or (9) 6.35, 9.31, 10.79, 12.93, 13.93, 14.47, 15.48, 15.86, 17.56, 17.78, 18.12, 18.50, 19.10, 19.82, 20.11, 20.99, 21.27, 22.41, 23.60, 23.89, 24.70, 25.14, 25.55, 25.93, 26.81, 28.07, 28.80, 29.49, 32.01, 32.58, 33.23.

[0046] According to a preferred embodiment of all aspects of the present invention, meglumine salt Form A exhibits at least the following characteristic XPRD peaks: 6.35, 13.93, 15.48, 15.86, 20.99, 22.41, 23.60 and 28.07.

[0047] In FIG. 1, a characteristic XRPD spectrum of crystalline Form A of the meglumine salt of sulfasalazine is shown.

[0048] According to another or additional embodiment of any aspect of the invention, crystalline Form A of the piperazine salt of sulfasalazine exhibits at least the following characteristic X-ray powder diffraction (XPRD) peaks (expressed in 2θ°±0.2°) (in accordance with United States Pharmacopeia Convention. X-Ray Diffraction, General Test (USP941)): <941> United States Pharmacopeia, 25 th ed. Rockville, MD: United States Pharmacopeial Convention; 2002: 2088-2089): (1) 11.95, 12.30 and 16.42, or (2) December 30, December 93 and 15.01, or (3) 11.95, 12.30, 12.93, 16.42, 17.87, and 20.36; or (4) 8.11, 11.95, 12.30, 15.01, 16.42, 17.87, 20.36, and 20.74; or (5) 11.95, 12.30, 12.93, 15.01, 16.42, 17.87, 20.36, 20.74, 22.41, and 23.41; or (6) 11.95, 15.01, 16.42, 17.87, 20.36, 20.74, 23.41, 24.01, 24.67, 24.99, and 26.09; or (7) 8.11, 11.95, 12.30, 12.93, 15.01, 16.42, 17.87, 20.36, 20.74, 22.41, 23.41, 24.01, 24.67, 24.99, and 26.09, or (8) 11.95, 12.30, 12.93, 15.01, 16.42, 17.87, 20.36, 20.74, 22.41, 23.41, 24.01, 24.67, 24.99, 26.09, 26.81, 27.73, and 28.80; or (9) 8.11, 11.95, 12.30, 12.93, 15.01, 16.42, 17.87, 20.36, 20.74, 22.41, 23.41, 24.01, 24.67, 24.99, 26.09, 26.81, 27.73, 28.80, 29.80 and 30.43.

[0049] According to a preferred embodiment of all aspects of the present invention, piperazine salt Form A exhibits at least the following characteristic XPRD peaks: 12.3, 12.93, 15.0, 16.42, 22.41 and 23.41.

[0050] FIG. 2 shows a characteristic XRPD spectrum of crystalline Form A of the piperazine salt of sulfasalazine of the present invention.

[0051] According to still another or additional embodiment of any aspect of the present invention, crystalline Form A of the diethylamine salt of sulfasalazine exhibits at least the following characteristic X-ray powder diffraction (XPRD) peaks (expressed in 2θ°±0.2°) (in accordance with United States Pharmacopeia Convention. X-Ray Diffraction, General Test (USP941)): <941> United States Pharmacopeia, 25 th ed. Rockville, MD: United States Pharmacopeial Convention; 2002: 2088-2089): (1) 7.16, 11.48, and 18.78, or (2) 10.50, 15.41, and 21.87; or (3) 7.16, 10.50, 11.48, 18.78, 21.65, and 21.87; or (4) 10.50, 11.48, 12.42, 14.38, 15.41, 16.64, 18.78, and 21.87; or (5) 7.16, 10.50, 11.01, 11.48, 13.87, 15.92, 16.64, 18.78, 21.08, 21.65, and 22.15; or (6) 7.16, 10.50, 11.01, 11.48, 12.42, 13.87, 14.38, 15.41, 15.92, 16.64, 17.19, 18.28, 18.78, 21.08, 21.65, 21.87, and 22.15; or (7) 7.16, 10.50, 11.48, 12.42, 13.87, 14.38, 15.41, 15.92, 16.64, 20.52, 21.08, 21.65, 21.87, 22.15, 22.47, 23.16, 23.63, 24.14, and 25.11, or (8) 7.16, 10.50, 11.01, 11.48, 12.42, 13.87, 14.38, 15.41, 15.92, 16.64, 17.19, 18.28, 18.78, 20.52, 21.08, 21.65, 21.87, 22.15, 22.47, 23.16, 23.63, 24.14, and 25.11, or (9) 7.16, 10.50, 11.01, 11.48, 12.42, 13.87, 14.38, 15.41, 15.92, 16.64, 17.19, 18.28, 18.78, 20.52, 21.08, 21.65, 21.87, 22.15, 22.47, 23.16, 23.63, 24.14, 25.11, 26.94, 27.95, 28.92, 29.46.

[0052] It is further disclosed that, in accordance with a preferred embodiment of all aspects of the present invention, the diethylamine salt Form A exhibits at least the following characteristic XPRD peaks: 7.16, 10.50, 11.48, 18.78, 21.65 and 21.87.

[0053] FIG. 3 shows a characteristic XRPD spectrum of crystalline Form A of the diethylamine salt of sulfasalazine of the present invention.

[0054] According to still another or additional embodiment of any of the aspects of the present invention, the second polymorphic Form B crystalline of the diethylamine salt of sulfasalazine exhibits at least the following characteristic X-ray powder diffraction (XPRD) peaks (expressed in 2θ°±0.2°) (in accordance with United States Pharmacopeia Convention. X-Ray Diffraction, General Test (USP941)): <941> United States Pharmacopeia, 25 th ed. Rockville, MD: United States Pharmacopeial Convention; 2002: 2088-2089): (1) 6.85, 17.82, and 22.75, or (2) 11.38, 20.58, and 23.98, or (3) 6.85, 11.38, 17.62, 20.58, and 22.75; or (4) 6.85, 11.38, 11.70, 17.62, 20.58, 22.75, and 23.98; or (5) 11.38, 11.70, 15.29, 16.71, 17.62, 19.92, 20.58, 21.30, 22.75, 23.63, and 23.98; or (6) 6.85, 11.38, 11.70, 14.78, 15.29, 15.70, 16.71, 17.62, 19.92, 20.20, 20.58, 21.30, 22.75, 23.63, 23.98, and 28.61; or (7) 6.85, 11.38, 11.70, 14.78, 15.29, 15.70, 16.71, 17.62, 19.92, 20.20, 20.58, 21.30, 22.75, 23.63, 23.98, 25.05, 25.71, 26.81, 27.95, and 28.61; or (8) 6.85, 11.38, 11.70, 14.78, 15.29, 15.70, 16.71, 17.62, 19.92, 20.20, 20.58, 21.30, 22.75, 23.63, 23.98, 25.05, 25.71, 26.81, 27.51, 27.95, 28.61, 29.14, 31.06.

[0055] According to a preferred embodiment of all aspects of the present invention, diethylamine salt Form B exhibits at least the following characteristic XPRD peaks: 6.85, 11.38, 11.70, 17.62, 20.58, 22.75 and 23.98.

[0056] FIG. 4 shows a characteristic XRPD spectrum of crystalline Form B of the diethylamine salt of sulfasalazine of the present invention.

[0057] The salt crystalline forms of sulfasalazine, i.e., Form A crystalline of the D(-)-N-methylglucamine (meglumine) salt of sulfasalazine, Form A crystalline of the piperazine salt of sulfasalazine, Form A crystalline of the diethylamine salt of sulfasalazine and Form B crystalline of the diethylamine salt of sulfasalazine, are preferably used in solvate- and / or hydrate-free form. Such solvate-free, especially hydrate-free (anhydrous) forms may exhibit advantageous physicochemical properties when preparing pharmaceutical compositions as solvate-free, especially anhydrous forms, and in particular support the physical and chemical stability of the active ingredient sulfasalazine and the pharmaceutical composition, respectively, over the storage period.

[0058] The crystalline organic salts of 2-hydroxy-5-[2-[4-[(2-pyridinylamino)sulfonyl]phenyl]diazenyl]-benzoic acid (sulfasalazine), where the organic salt is preferably selected from diethylamine, piperazine and D-(-)-N-methylglucamine (meglumine), A1: providing sulfasalazine free acid form in a suitable solvent; B1: Providing an organic amine-containing component in a suitable solvent, preferably selected from meglumine, piperazine and diethylamine; C1: mixing the sulfasalazine solution of step A1) with the organic amine-containing component solution of step B1) at room temperature, preferably 19°C to 25°C; and D1: isolating the crystals of diethylamine sulfasalazine Form A or a solvate thereof, or the crystals of piperazine sulfasalazine Form A or a solvate thereof, or the crystals of meglumine sulfasalazine Form A or a solvate thereof formed in the solution of step C1); or A2: Providing sulfasalazine free acid form in a suitable solvent; B2: Providing an organic amine-containing component, preferably selected from meglumine, diethylamine, in a suitable solvent; C2: mixing the sulfasalazine solution of step A2) with the organic amine-containing component solution of step B2), wherein the amine-containing component is in at least a 5% molar excess relative to the sulfasalazine, more preferably at least a 10% molar excess, more preferably at least a 20% molar excess; and D2a: Concentrating the mixture formed in step C2) to separate crystals of meglumine sulfasalazine Form A or a solvate thereof or crystals of diethylamine sulfasalazine Form B or a solvate thereof; or D2b: adding an additional solvent to the mixture formed in step C2), wherein the additional solvent is different from the solvent used in steps A2) and B2), and isolating the crystals of meglumine sulfasalazine Form A or a solvate thereof or the crystals of diethylamine sulfasalazine Form B or a solvate thereof; wherein the organic amine-containing component is not tris(hydroxymethyl)aminomethane (tromethane base).

[0059] If the sulfasalazine salt crystalline form contains residual solvates / hydrates, an appropriate drying step is followed.

[0060] According to step B) of the manufacturing method of the present invention for obtaining the pharmaceutical composition of the present invention, an organic amine-containing component suitable for pharmaceutical use is provided, preferably selected from meglumine, piperazine and diethylamine, where the organic amine-containing component is not tris(hydroxymethyl)aminomethane (tromethane base). The organic amine-containing component is preferably provided in powder form.

[0061] According to step C) of the inventive process for obtaining the inventive pharmaceutical composition, one or more pharmaceutical excipients and optionally one or more further active ingredients are further provided.

[0062] According to all aspects of the present invention, the one or more pharmaceutical additives provided in step C) are preferably selected from the group of excipients, binders, lubricants, disintegrants, surfactants / solubilizers, alkaline additives, antioxidants; pH buffers; colorants; dyes; flavorings; thickeners; plasticizers; solvents; anti-tacking agents; antistatic agents; antifoaming agents; dispersing agents; other agents; and hard and soft gelatin capsule forming agents.

[0063] Additionally or alternatively, the one or more further active ingredients of step C) are preferably selected from the group consisting of methotrexate, hydroxychloroquine, steroids, leflunomide, azathioprine, tofacitinib, monoclonal antibodies such as the anti-tumor necrosis factor alpha monoclonal antibodies infliximab, adalimumab and golimumab, more preferably methotrexate and hydroxychloroquine, preferably non-steroidal anti-inflammatory drugs; preferably non-selective cyclo-oxygenase COX-1 / COX-2 inhibitors, whether applied locally or systemically, such as piroxicam, diclofenac, propionic acids such as naproxen, flurbiprofen, fenoprofen, ketoprofen and ibuprofen, fenamates such as mefenamic acid, indomethacin, sulindac, azapropazone, pyrazolones such as phenylbutazone, salicylates, For example aspirin, selective COX-2 inhibitors such as meloxicam, celecoxib, rofecoxib, valdecoxib, lumiracoxib, parecoxib and etoricoxib, cyclooxygenase inhibitors that donate nitric oxide (CINOD); glucocorticoids, preferably flunisolide, triamcinolone acetonide, betamethasone dipropionate, budesonide, fluticasone propionate, ciclesonide or mometasone. furancarboxylates; methotrexate; leflunomide; hydroxychloroquine; d-penicillamine; diacerein; dietary supplements, preferably glucosamine; gold preparations, preferably auranofin; cytokines or agonists or antagonists of cytokine function; monoclonal antibodies targeting B lymphocytes, preferably CD20 (rituximab); MRA-aIL16R; T-lymphocytes; CTLA4-Ig; HuMax 11-15; modulators of chemokine receptor function, preferably antagonists of CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCRlO and CCR11 (CC family), CXCRl, CXCR2, CXCR3, CXCR4 and CXCR5 (CXC family) and CX3CR1 (C-X3-C family);Azathioprine, tofacitinib, monoclonal antibodies such as anti-tumor necrosis factor alpha monoclonal antibodies infliximab, adalimumab and golimumab; interleukin 1 receptor antagonists such as anakinra; etanercept and abatacept; more preferably methotrexate and hydroxychloroquine.

[0064] According to step D) of the manufacturing method of the present invention for obtaining the pharmaceutical composition of the present invention, a therapeutically effective amount of sulfasalazine of step A) is mixed with an appropriate amount of an organic amine-containing component of step B), as well as one or more pharmaceutical excipients and optionally one or more further active ingredients of step C) to form a pharmaceutical composition for oral administration.

[0065] According to another or additional preferred embodiment of all aspects of the present invention, a core material comprising sulfasalazine and / or an organic sulfasalazine amine salt is formed in step D), wherein the core material is preferably D1: Wet extrusion, wet spheronization, hot melt extrusion, hot melt pelletization, fluidized bed spray encapsulation, balling and compression The compound is produced by a method selected from the group consisting of:

[0066] More preferably, according to another or additional preferred embodiment of all aspects of the present invention, the one or more pharmaceutical additives in step C) comprise or consist as excipients of seed materials, in particular water-insoluble seed materials, preferably selected from the group consisting of oxidized materials, cellulose materials, organic polymeric materials or mixtures thereof, and / or water-soluble seed materials, such as nonpareils, preferably selected from the group consisting of inorganic salt materials, sugar materials, starch materials or mixtures thereof, and in step D) the core material comprises D2: Prepared by coating a seed material provided in step C) with sulfasalazine provided in step A) and an organic amine component provided in step B), and optionally further with a pharmaceutical additive provided in step C), preferably selected from the group consisting of a binder, a surfactant, an excipient, a lubricant, a disintegrant, an alkaline additive and a buffering agent.

[0067] According to another or additional preferred embodiment of all aspects of the present invention, the process of the present invention further comprises or consists of applying one or more coating layers to the core material provided in D) to form a pharmaceutical composition for oral administration, said process comprising the following steps: E: Optionally, coating the core material produced in step D) with one or more separating layers, preferably selected from pH buffers; F: Coating the core material produced in step D) or the core material comprising one or more separating layers produced in step E) with an enteric coating; G: Optionally, coating the enteric coated core material of step F) with an overcoating layer; and H: Optionally, formulating the enteric coated core material of step F) or the enteric coated and overcoated core material of step G) into a tablet or capsule. It further comprises or consists of:

[0068] According to an alternative or additional preferred embodiment of all aspects of the present invention, the coating in any of steps E) to H) is preferably produced by powder or solution layering, more preferably by spray drying or spray congealing.

[0069] According to another or additional preferred embodiment of all aspects of the present invention, prior to coating the compressed core material with an enteric coating in step F), the core material of step D) or the core material comprising one or more separating layers of step E) is compressed to form a tablet.

[0070] According to another or additional preferred embodiment of all aspects of the invention, the one or more pharmaceutical excipients suitable for forming the one or more separating layers of step E) are preferably film formers, preferably sugars, polyethylene glycols, polyvinylpyrrolidones, polyvinyl alcohols, polyvinyl acetates, hydroxypropylcellulose, methylcellulose, ethylcellulose, hydroxypropylmethylcellulose and sodium carboxymethylcellulose; antioxidants, preferably magnesium oxide, hydroxide or carbonate, aluminium or calcium hydroxide, carbonate or silicate; aluminium / magnesium complex compounds, e.g. Al2O3·6MgO·CO2·12H2O, Mg6Al2(OH) 16 CO3·4H2O, MgO·Al2O3·2SiO2·nH2O, aluminum hydroxide / sodium bicarbonate coprecipitate; and pharma- ceutically acceptable pH buffers, such as sodium, potassium, calcium, magnesium and aluminum salts of phosphate, carbonate, citric acid or other suitable weak inorganic or organic acids; or suitable organic bases, such as basic amino acids and their salts; plasticizers; colorants; pigments; excipients; and anti-adhesives / anti-static agents, preferably selected from the group consisting of magnesium stearate, titanium dioxide and talc.

[0071] According to another or additional preferred embodiment of all aspects of the present invention, the one or more pharmaceutical excipients suitable for forming the enteric coating of step F) are preferably selected from the group consisting of film-forming agents, preferably methacrylic acid copolymers, cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, polyvinyl acetate phthalate, cellulose acetate trimellitate, carboxymethylethylcellulose and shellac; plasticizers, preferably triacetin, citrate esters, phthalates, dibutyl sebacate, cetyl alcohol, polyethylene glycol and polysorbates; dispersing agents; colorants; dyes; other agents, such as poly(ethyl acrylate, methyl methacrylate); anti-adherents / anti-foaming agents, agents that increase the thickness of the film and / or reduce the diffusion of acidic gastric juices into the core material. More preferably, according to all aspects of the present invention, the thickness of the enteric coating layer is at least 5 μm, more preferably at least 10 μm.

[0072] According to another or additional preferred embodiment of all aspects of the invention, the one or more pharmaceutical excipients suitable for forming the overcoating of step G) are selected from the group consisting of film formers, preferably sugars, polyethylene glycols, polyvinylpyrrolidones, polyvinyl alcohols, polyvinyl acetates, hydroxypropylcellulose, methylcellulose, ethylcellulose, hydroxypropylmethylcellulose and sodium carboxymethylcellulose; plasticizers; colorants; pigments; excipients; anti-adherents; antistatic agents, preferably magnesium stearate, titanium dioxide and talc.

[0073] According to another or additional preferred embodiment of all aspects of the invention, step H) capsules are i. as a soft gelatin capsule, preferably with one or more further pharmaceutical excipients selected from the group consisting of surfactants / solubilizers, preferably tocopheryl polyethylene glycol succinate (TPGS), vegetable oils and / or polyethylene glycol; ii. As a hard gelatin capsule, with one or more additional pharmaceutical additives selected from the group consisting of surfactants / solubilizers, preferably tocopheryl polyethylene glycol succinate (TPGS). is formed.

[0074] According to a second aspect, the present invention relates to a pharmaceutical composition for oral administration obtainable according to the process of the invention.

[0075] According to another or additional preferred embodiment of all aspects of the invention, the pharmaceutical composition for oral administration of the invention is a solid pharmaceutical composition, preferably selected from the group consisting of granules, preferably multi-unit pellet systems (MUPS), tablets, preferably multi-unit pellet tablets (MUP tablets), capsules and powders; a liquid pharmaceutical composition, preferably selected from the group consisting of syrups and suspensions.

[0076] According to another embodiment of the pharmaceutical composition of the invention for oral administration, the composition of the invention is alternatively or additionally suitable for dispersion in an aqueous liquid having a neutral or slightly acidic pH prior to oral administration or feeding via a nasogastric tube.

[0077] Alternatively, when the pharmaceutical composition of the present invention can be in the form of a tablet formulation, one, two, three, four or more pharmaceutical tablet additives are preferably selected from the group consisting of fillers, binders, disintegrants, lubricants, etc., and compressed into a tablet.

[0078] Alternatively, when the pharmaceutical composition of the present invention can be in the form of a liquid preparation for oral administration, for example in the form of a syrup or suspension, the pharmaceutical additives contained in such a liquid preparation can include a mixture of sugar and / or ethanol, water, glycerol and propylene glycol, preferably buffered to an appropriate pH. If desired, such a liquid preparation of the present invention can include one, two, three, four or more additional additives, preferably selected from the group consisting of coloring agents, flavoring agents, saccharin and / or carboxymethylcellulose as a thickening agent or other additives known to those skilled in the art.

[0079] According to yet another or additional preferred embodiment of all aspects of the invention, the total therapeutically effective amount of sulfasalazine as the free acid or organic salt per dose of the pharmaceutical composition for oral administration is in the range of 10 mg to 2,000 mg, preferably 10 mg, 20 mg, 25 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 75 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg, 125 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 175 mg, 180 mg, 190 mg, 200 mg, 210 mg, 220 mg, 225 mg, 230 mg, 240 mg, 250 mg, 260 mg, 270 mg, 275 mg, 280 mg, 290 mg, 300 mg, 310 mg, 320 mg, 325 mg, 330 mg, 340 mg, 350 mg, 360 mg, 370 mg, 380 mg, 390 mg, 400 mg, 410 mg, 420 mg, 430 mg, 440 mg, 450 mg, 460 mg, 470 mg, 480 mg, 490 mg, 500 mg, 510 mg, 520 mg, 530 mg, 540 mg, 550 mg, 560 mg, 570 mg, 580 mg, 590 mg, 600 mg, 610 mg, 620 mg, 630 mg, 640 mg, 650 mg, 660 mg, 670 mg, 680 mg, 690 mg, 700 mg mg, 350 mg, 360 mg, 370 mg, 375 mg, 380 mg, 390 mg, 400 mg, 410 mg, 420 mg, 425 mg, 430 mg, 440 mg, 450 mg, 460 mg, 470 mg, 475 mg, 480 mg, 490 mg, 500 mg, 525 mg, 550 mg, 575 mg, 600 mg, 625 mg, 650 mg, 675 mg, 700 mg, 725 mg, 750 mg, 775 mg, 800 mg, 825 mg, 850 mg, 875 mg, 900 mg, 925 mg, 950 mg, 975 mg, 1,000 mg, 1,025 mg, 1,050 mg, 1,075 mg, 1,100 mg, 1,125 mg, 1,150 mg, 1,175 mg, 1,200 mg, 1,225 mg, 1,250 mg, 1,275 mg, 1,300 mg, 1,325 mg, 1,350 mg, 1,375 mg, 1,400 mg, 1,425 mg, 1,450 mg, 1,475 mg, 1,500 mg, 1,525 mg, 1,550 mg, 1,575 mg, 1,600 mg, 1,625 mg, 1,650 mg, 1,675 mg, 1,700 mg, 1,725 ​​mg, 1,750 mg, 1,775 mg, 1,800 mg, 1,825 mg, 1,850 mg, 1,875 mg, 1,900 mg, 1,925 mg, 1,More preferably, a single unit dose of the pharmaceutical composition of the present invention preferably contains <500 mg, ≦450 mg, ≦400 mg, ≦375 mg, ≦250 mg of sulfasalazine, preferably as the free acid and / or the organic amine salt.

[0080] The salt crystalline forms of sulfasalazine of the present invention and its in vivo metabolites sulfapyridine and 5-ASA are useful as modulators of the function of various inflammatory cell types, such as T cells, B cells, dendritic cells, neutrophils, NK cells and mast cells.For example, in experiments studying the proliferation of human synovial cells from patients with rheumatoid arthritis, the proliferation of these cells and the production of IL-1B and IL-6 by these cells were shown to be significantly inhibited.In these experiments, it could be shown that the overexpression of c-fos mRNA is inhibited by the crystalline forms of sulfasalazine of the present invention.Therefore, the crystalline forms of sulfasalazine of the present invention can be administered to mammals, including humans, for the treatment of, in particular, autoimmune, inflammatory, proliferative and hyperproliferative diseases and immune-mediated diseases.

[0081] Thus, according to a third aspect, the pharmaceutical composition of the invention comprises: i) a human disease or condition in which modulation of inflammatory cells is beneficial; ii) diseases or conditions relating to bone or joints, preferably arthritis associated with or including osteoarthritis, primary or secondary to, for example, congenital hip dysplasia; cervical and lumbar spondylitis, and lower back and neck pain; rheumatoid arthritis and Still's disease; seronegative spondyloarthropathy, such as ankylosing spondylitis, psoriatic arthritis, reactive arthritis and undifferentiated spondarthropathy, septic arthritis and other arthopathies and bone disorders associated with infections, such as tuberculosis, e.g. Pott's disease and Ponce's disease; acute and chronic crystal-induced synovitis, such as urate gout, calcium pyrophosphate deposition disease, and calcium apatite associated tendonitis. tendon), bursal and synovial inflammation; Behcet's disease; primary or secondary Sjogren's syndrome; systemic sclerosis and localized scleroderma; systemic lupus erythematosus, mixed connective tissue disease, and undifferentiated connective tissue disease; inflammatory myopathies, such as dermatomyositis and polymyositis; polymyalgia rheumatica; juvenile arthritis, such as idiopathic inflammatory arthritis of any joint location and associated syndrome, and rheumatic fever and its systemic complications; vasculitis, such as giant cell arteritis, Takayasu's arteritis, Churg-Strauss syndrome, polyarteritis nodosa, microscopic polyarteritis, and vasculitis associated with viral infections, hypersensitivity reactions, cryoglobulins, and paraproteins; lower back pain; Familial Mediterranean Fever, Muckle-Wells syndrome, and Familial Hibernian Fever, Kikuchi's disease; a disease or condition selected from the group consisting of drug-induced joint pain, tendonitis, and myopathy; and iii) diseases or conditions relating to the digestive tract, preferably selected from the group consisting of eosinophilic gastroenteritis, mastocytosis, Crohn's disease, colitis, e.g. ulcerative colitis, proctitis; celiac disease, irritable bowel syndrome, and food-related allergies that may affect areas distant from the intestine, e.g. migraine, rhinitis or eczema. It is used in the treatment of.

[0082] According to another aspect, the present invention relates to the use of the pharmaceutical composition of the present invention in the manufacture of a medicament for / in the treatment of the above disorders or conditions.

[0083] According to another aspect, the present invention relates to a method for treating one or more of the above disorders or conditions in a patient suffering from or at risk of said disease or condition, comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition of the present invention.

[0084] According to all aspects, the present invention also relates to combination therapy in which one or more crystalline salt forms of sulfasalazine of the present invention or pharmaceutical compositions of the present invention are administered concurrently (simultaneously) or sequentially or as a combined pharmaceutical formulation or combined dosing regimen with one or more active ingredients (therapeutic agents) for the treatment of one or more of the diseases and conditions, preferably the above mentioned diseases and conditions.

[0085] In the context of this specification, the term "treatment" also includes "prophylaxis", unless specifically stated to the contrary. The terms "therapeutic" and "therapeutically" should be construed accordingly.

[0086] Prevention is expected to be particularly relevant to the treatment of patients suffering from, or otherwise considered to be at high risk of, the disease or condition in question. Those at risk of developing a particular disease or condition generally include those who have a family history of the disease or condition, or those who have been identified by genetic testing or screening to be predisposed to developing the disease or condition.

[0087] According to the inventive treatment of the above inflammatory diseases, the sulfasalazine of the pharmaceutical composition of the present invention may be used in the same or separate pharmaceutical composition with one, two, three or more active ingredients (therapeutic agents), which are preferably selected from the group consisting of the following therapeutic agents: - nonsteroidal anti-inflammatory drugs (NSAIDs), for example nonselective cyclo-oxygenase COX-1 / COX-2 inhibitors, whether applied topically or systemically (e.g. piroxicam, diclofenac, propionic acids, e.g. naproxen, flurbiprofen, fenoprofen, ketoprofen and ibuprofen, fenamates, e.g. mefenamic acid, indomethacin, sulindac, azapropazones, pyrazolones, e.g. phenylbutazone, salicylates, e.g. aspirin); selective COX-2 inhibitors (e.g. meloxicam, diclofenac, propionic acids, e.g. naproxen, flurbiprofen, fenoprofen, ketoprofen and ibuprofen); cicam, celecoxib, rofecoxib, valdecoxib, lumiracoxib, parecoxib and etoricoxib); cyclooxygenase inhibitors that donate nitric oxide (CINOD); glucocorticoids (whether administered by topical, oral, intramuscular, intravenous or intra-articular routes); methotrexate, leflunomide, hydroxychloroquine, d-penicillamine; auranofin and other parenteral or oral gold preparations; analgesics; diacerein; intra-articular treatments, such as hyaluronic acid derivatives; and dietary supplements, such as glucosamine. - agonists or antagonists of cytokines or cytokine function (including drugs acting on cytokine signaling pathways, e.g. modulators of the SOCS system), such as α-, β- and γ-interferon; insulin-like growth factor type I (IGF-I); interleukins (IL), such as IL-1 to 23, and interleukin antagonists or inhibitors, such as anakinra; tumor necrosis factor alpha (TNF-α) inhibitors, such as anti-TNF monoclonal antibodies (e.g. infliximab, adalimumab and golimumab) and TNF receptor antagonists, such as immunoglobulin molecules (e.g. etanercept) and low molecular weight drugs, such as pentoxifylline. - Monoclonal antibodies targeting B-lymphocytes (e.g. CD20 (rituximab); MRA-aIL16R and T-lymphocytes, CTLA4-Ig; HuMax 11-15). - modulators of chemokine receptor function, such as CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCRlO and CCR11 (CC family); antagonists of CXCRl, CXCR2, CXCR3, CXCR4 and CXCR5 (CXC family) and the CX3CRl C-X3-C family. - matrix metalloproteases (Tv-IMP), i.e. stromelysin, collagenase and gelatinase, as well as aggrecanase; in particular collagenase-1 (MMP-1), collagenase-2 (MMP-8), collagenase-3 (MMP-13), stromelysin-1 (MMP-3), stromelysin-2 (MMP-10), and stromelysin-3 (MMP-11) and inhibitors of MMP-9 and MMP-12, such as doxycycline. - leukotriene biosynthesis inhibitors, 5-lipoxygenase (5-LO) inhibitors or 5-lipoxygenase-activating protein (FLAP) antagonists, such as; zileuton; ABT-761; fenleuton; tepoxalin; Abbott-79175; Abbott-85761; N-(5-substituted)-thiophene-2-alkylsulfonamides; 2,6-di-tert-butylphenol hydrazones; methoxytetrahydropyrans, such as Zeneca ZD-213S; compound SB-210661; pyridinyl-substituted 2-cyanonaphthalene compounds, such as L-739,010; 2-cyanoquinoline compounds, such as L-746,530; or indole or quinoline compounds, such as MK-591, MK-886, and BAYx1005. - Leukotriene (LT) B4, LTC4, LTD4 and LTE4 receptor antagonists selected from the group consisting of phenothiazine-3-ls, such as L-651,392; amidino compounds, such as CGS-25019c; benzoxalamines, such as ontazolast; and compounds such as zafiruukast, ablukast, montelukast, pranlukast, verlukast (MK-679), RG-12525, Ro-245913, iralukast (CGP 45715A), and BAYx7195. - phosphodiesterase (PDE) inhibitors, such as methylxanthanines, e.g. theophylline and aminophylline; selective PDE isoenzyme inhibitors, such as PDE4 inhibitors, inhibitors of the isoform PDE4D, e.g. apremilast or inhibitors of PDE5. - Endothelin antagonists, such as Tezosentan, Bosentan, Macitentan, Enrasentan and Sixtasentan. - Angiotensin II antagonists, such as azilsartan, losartan, valsartan, candesartan and telmisartan. - Dual antagonists against both the angiotensin II and endothelin A receptors (DARAs), as disclosed, for example, in WO2000001389 and WO2001044239. - an adenosine A2a agonist, such as CGS-21680, and / or an adenosine A3 agonist, such as IB-MECA, and / or an adenosine A2b antagonist.The present invention further relates to a combination of a compound of the invention with a histamine type 1 receptor antagonist, such as cetirizine, loratadine, desloratadine, fexofenadine, acrivastine, terfenadine, astemizole, azelastine, levocabastine, chlorpheniramine, promethazine, cyclizine or mizolastine, applied orally, topically or parenterally. - Proton pump inhibitors (e.g. omeprazole) or gastroprotective histamine type 2 receptor antagonists. - Histamine type 4 receptor antagonist. - alpha1 / alpha2 adrenergic receptor agonist vasoconstrictor sympathomimetics, such as propylhexedrine, phenylephrine, phenylpropanolamine, ephedrine, pseudoephedrine, naphazoline hydrochloride, oxymetazoline hydrochloride, tetrahydrozoline hydrochloride, xylometazoline hydrochloride, tramazoline hydrochloride or ethylnorepinephrine hydrochloride. - anticholinergics, for example muscarinic receptor (M1, M2 and M3) antagonists, such as atropine, hyoscine, glycopyrrolate, ipratropium bromide, tiotropium bromide, oxitropium bromide, pirenzepine or telenzepine. - beta-adrenergic receptor agonists (including beta-receptor subtypes 1-4), such as isoprenaline, salbutamol, formoterol, salmeterol, terbutaline, orciprenaline, bitolterol mesylate or pirbuterol, or their chiral enantiomers. - chromones, such as sodium cromoglycate or nedocromil sodium.The invention still further relates to combinations of the compounds of the invention with glucocorticoids, such as flunisolide, triamcinolone acetonide, betamethasone dipropionate, budesonide, fluticasone propionate, ciclesonide or mometasone furoate. - Drugs that modulate nuclear hormone receptors, e.g. PPARs. - Immunoglobulins (Ig) or Ig preparations or antagonists or antibodies that modulate Ig function, such as anti-IgE (e.g. omalizumab). - Another systemically or topically applied anti-inflammatory drug, such as thalidomide or its derivatives, retinoids, dithranol or calcipotriol. - aminosalicylates and sulfapyridines, such as sulfasalazine, mesalazine, balsalazide and olsalazine; and immunomodulators, such as thiopurines, and corticosteroids, such as budesonide. Preferably, the amount of further aminosalicylates and sulfapyridines is less than the amount of the sulfasalazine crystalline form of the invention per unit dosage form. - antibacterial drugs, such as penicillin derivatives, tetracyclines, macrolides, beta-lactams, fluoroquinolones, metronidazole, inhaled aminoglycosides; antiviral drugs, such as acyclovir, famciclovir, valacyclovir, ganciclovir, cidofovir, amantadine, rimantadine, ribavirin, zanamavir and oseltamavir; protease inhibitors, such as indinavir, nelfinavir, ritonavir and saquinavir; nucleoside reverse transcriptase inhibitors, such as didanosine, lamivudine, stavudine, zalcitabine or zidovudine; or non-nucleoside reverse transcriptase inhibitors, such as nevirapine or efavirenz. - cardiovascular drugs, such as calcium channel blockers, beta-adrenergic receptor blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin 2 receptor antagonists; lipid-lowering drugs, such as statins or fibrates; modulators of blood cell morphology, such as pentoxifylline; thrombolytic or anticoagulant drugs, such as platelet aggregation inhibitors. - antidepressants (e.g. sertraline), anti-Parkinson's drugs (e.g. deprenyl, L-dopa, ropinirole, pramipexole, MAOB inhibitors such as selegiline and rasagiline, comP inhibitors such as tasmar, A-2 inhibitors, dopamine reuptake inhibitors, NMDA antagonists, nicotinic agonists, dopamine agonists or inhibitors of neuronal nitric oxide synthase), or anti-Alzheimer's drugs such as donepezil, rivastigmine, tacrine, COX-2 inhibitors, propentofylline or metrifonate. - Medications for the treatment of acute or chronic pain, such as centrally or peripherally acting analgesics (e.g. opioids or derivatives thereof), carbamazepine, phenytoin, sodium valproate, amitryptiline or other antidepressants, paracetamol, or nonsteroidal anti-inflammatory drugs. - Parenterally or topically applied (including inhaled) local anaesthetics, such as lignocaine or its derivatives. - Anti-osteoporosis drugs, for example hormonal agents, such as raloxifene, or biphosphonates, such as alendonic acid. - one or more drugs selected from the group consisting of: (i) tryptase inhibitors; (ii) platelet activating factor (PAF) antagonists; (iii) interleukin converting enzyme (ICE) inhibitors; (iv) IMPDH inhibitors; (v) adhesion molecule inhibitors, e.g. VLA-4 antagonists; (vi) cathepsins; (vii) kinase inhibitors, e.g. inhibitors of tyrosine kinases (e.g. Btk, Itk, Jak3 or MAP, e.g. tofacitinib, gefitinib or imatinib mesylate), serine / threonine kinases ( For example, inhibitors of MAP kinases, e.g. p38, INK, protein kinase A, B or C, or inhibitors of κB kinases, e.g. IKK1, IKK2 or IKK3, or kinases involved in cell cycle control (e.g. cyclin-dependent kinases); (viii) glucose-6-phosphate dehydrogenase inhibitors; (ix) kyrin-B1 or -B2-receptor antagonists; (x) anti-gout drugs, e.g. colchicine; (xi) xanthine oxidase inhibitors, e.g. allopurinol; (xii) uricosurics. (xiii) growth hormone secretagogues; (xiv) transforming growth factor (TGFβ); (xv) platelet-derived growth factor (PDGF); (xvi) fibroblast growth factors, such as basic fibroblast growth factor (bFGF); (xvii) granulocyte-macrophage colony-stimulating factor (GM-CSF); (xviii) capsaicin cream; (xix) tachykinin NK1 or NK3 receptor antagonists, such as NKP-608C, SB -233412 (talnetant) or D-441S; (xx) elastase inhibitors, such as LT-77 or ZD-0892; (xxi) TNF-α converting enzyme inhibitors (TACE); (xxii) inducible nitric oxide synthase (iNOS) inhibitors; (xxiii) chemoattractant receptor homologues expressed in TH2 cells (e.g. CRTH2 antagonists); (xxiv) inhibitors of P38; (xxv) drugs that modulate the function of Toll-like receptors (TLRs), (xxvi) drugs that modulate the activity of purinergic receptors such as P2X7;or (xxvii) inhibitors of transcription factor activation such as NFkB, API or STATS, (xxvii) drugs that modulate guanylate cyclase, such as riociguat (methyl-N-[4,6-diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methyl-carbaminate (IUPAC)); - one or more therapeutic agents for the treatment of cancer, preferably (i) antiproliferative / antineoplastic agents or combinations thereof used in clinical oncology, such as alkylating agents (e.g. cisplatin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulfan or nitrosoureas); antimetabolites (e.g. antifolates, such as fluoropyrimidines like 5-fluorouracil, or tegafur, raltitrexed, methotrexate, cytosine arabinoside, hydrochloride, cyclosporine, cyclopentasiloxane, cyclohexyl tert-butyl ether ... xyluria, gemcitabine or paclitaxel; antitumor antibiotics (e.g. anthracyclines, such as adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin or mithramycin); mitotic inhibitors (e.g. vinca alkaloids, such as vincristine, vinblastine, vindesine or vinorelbine, or taxoids, such as taxol or taxotere); or topoisomerase inhibitors (e.g. epipodophyllotoxins, e.g. etoposide, teniposide, amsacrine, topotecan or camptothecin); (ii) cytostatics, e.g. antiestrogens (e.g. tamoxifen, toremifene, raloxifene, droloxifene or iodoxyfene), estrogen receptor downregulators (e.g. fulvestrant), antiandrogens (e.g. bicalutamide, phytamide, nilutamide or cyproterone acetate), LHRH antagonists or LHRH antagonists. (iii) drugs that inhibit the invasion of cancer cells (e.g. metalloproteinase inhibitors like marimastat, or inhibitors of urokinase plasminogen activator receptor function);(iv) inhibitors of growth factor function, for example: growth factor antibodies (e.g. the anti-erbb2 antibody trastuzumab or the anti-erbb1 antibody cetuximab [C225]), farnesyltransferase inhibitors, tyrosine kinase inhibitors or serine / threonine kinase inhibitors, inhibitors of the epidermal growth factor family (e.g. EGFR family tyrosine kinase inhibitors, for example N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (gefitinib, AZDl 839), N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774) or 6-acrylamido-N-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)quinazolin-4-amine (CI 1033), inhibitors of the platelet derived growth factor family, or inhibitors of the hepatocyte growth factor family; (v) antiangiogenic agents, such as those that inhibit the action of vascular endothelial growth factor (e.g. the anti-vascular endothelial growth factor antibody bevacizumab, compounds disclosed in WO 97 / 22596, WO 97 / 30035, WO 97 / 32856 or WO 98 / 13354), or compounds acting by another mechanism (e.g. linomide, inhibitors of integrin αvβ3 function or angiostatin); (vi) vascular disorder agents, such as combretastatin A4, or compounds disclosed in WO 99 / 02166, WO 00 / 40529, WO 00 / 41669, WO 01 / 92224, WO 02 / 04434 or WO 02 / 08213; (vii) drugs used in antisense therapy, such as those directed against one of the above targets, e.g. ISIS 2503, anti-ras antisense; (viii) gene therapy approaches, such as approaches to replace abnormal genes, e.g. abnormal p53 or abnormal BRCA1 or BRCA2, GDEPT (gene directed enzyme prodrug therapy) approaches, such as those using cytosine deaminase, thymidine kinase or bacterial nitroreductase enzymes, and approaches to increase a patient's resistance to chemotherapy or radiotherapy, such as drugs used in multidrug resistance gene therapy;or (ix) a therapeutic agent selected from the group consisting of drugs used in immunotherapy approaches, such as ex vivo and in vivo approaches to increase the immunogenicity of patient tumor cells, such as transfection of cytokines, such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches to reduce T cell anergy, approaches using transfected immune cells, such as cytokine-transfected dendritic cells, approaches using cytokine-transfected tumor cell lines and approaches using anti-idiotypic antibodies; - one or more therapeutic agents for the treatment of airway disease, respiratory disease and / or inflammatory disease, such as chronic obstructive pulmonary disease and asthma. The sulfasalazine salt crystal form of the present invention can be administered by inhalation or oral route, and the drug (other drug) for the treatment of airway disease, respiratory disease and / or inflammatory disease, such as chronic obstructive pulmonary disease and asthma, can be independently selected to be administered by inhalation or oral route. The sulfasalazine salt crystal form of the present invention and other drugs can be administered in one pharmaceutical preparation or in separate pharmaceutical preparations. In the case of separate pharmaceutical preparations, the sulfasalazine salt crystal form of the present invention and other drugs can be administered simultaneously or sequentially or separately.

[0088] Depending on the therapeutic application, the dosage of the sulfasalazine salt crystalline forms of the present invention will of course vary depending on the mode of administration, the desired treatment and the intended disorder, but may typically range from 1 mg / kg to 50 mg / kg. EXAMPLES

[0089] The present invention is described below on the basis of exemplary embodiments, which serve merely as examples and do not limit the scope of the present protection. The exemplified features may be combined separately or in any (sub)combination with the general disclosure of all aspects of the invention above.

[0090] Example 1 Solubility of sulfasalazine in sulfasalazine, sulfasalazine meglumine salt form A and pharmaceutical compositions

[0091] HPLC The amount of dissolved sulfasalazine was determined by HPLC on a HP 1100 instrument using a Waters X-Bridge 3.5 μm C18 column (150 × 4.6 mm) and a gradient method, respectively. The mobile phase consisted of the following: Mobile phase (A): 1.13 g of sodium dihydrogen phosphate and 2.5 g of sodium acetate were dissolved in 1000 mL of purified water. The pH was then adjusted to 4.8 with acetic acid (100%). Mobile phase (B): 1 part of mobile phase A is mixed with 4 parts of chromatographic grade methanol. The flow rate was 1.0 mL / min, the injection volume was 5 μL, and the detection wavelength was 320 nm (HP DAD series 1100). The run time was 10 min. Quantification was performed using an external standard method. The quantitative method was validated for selectivity, reproducibility, and linearity. Samples are prepared in diluted ammonia R3 PhEur.

[0092] Step A 50 mg of sulfasalazine and meglumine salt form A of sulfasalazine were weighed into 4 mL glass vials containing 2 mL of water or FaSSIF-V2 medium, respectively, and stirred at room temperature (20-25°C) for 24 h, after which 20 mg of sulfasalazine and meglumine salt form A of sulfasalazine were added until a saturated solution was obtained. The saturated solution was filtered using a centrifugal filter (Nylon, 0.45 μM) and the clear supernatant was injected directly or after dilution with diluted ammonia PhEur, respectively.

[0093] Step B Sulfasalazine (1 g; 2.5 mmol) and meglumine (2 eq.) were dissolved in water under magnetic stirring at room temperature until complete dissolution. The resulting solution was further pre-diluted with phosphate buffer (pH 6.8) to a 1% v / v solution. The resulting phosphate buffer was diluted with dilute ammonia R3 before injection.

[0094] Step C Kolliphor HS 15 (Solutol HS 15, Ph.Eur. / USP, BASF, containing approximately 30% free propylene glycol), Kolliphor RH 40 (Cremophor RH 40, Ph.Eur. / USP, BASF) and TPGS-1000 (USP, Antares Health Products) (2 g) were each dissolved in 20 mL of water at approximately 60° C. To 10 mL of each resulting solution, 1000 mg of sulfasalazine and 735 mg of meglumine (1.5 equivalents) were added and stirred at room temperature for approximately 30 minutes until the sulfasalazine was completely dissolved, respectively.

[0095] [Table 1]

[0096] Example 2 Stability of Sulfapyridine in Pharmaceutical Compositions

[0097] HPLC The amount of dissolved sulfasalazine was determined by HPLC on an HP 1100 instrument using a Waters X-Bridge 3.5 μm C18 column (150 × 4.6 mm) and a gradient method. The mobile phase consisted of the following: Mobile phase (A): 1.13 g of sodium dihydrogen phosphate and 2.5 g of sodium acetate were dissolved in 1000 mL of purified water. The pH was then adjusted to 4.8 with acetic acid (100%). Mobile phase (B): 1 part of mobile phase A is mixed with 4 parts of chromatographic grade methanol. The flow rate was 1.0 mL / min, the injection volume was 5 μL, and the detection wavelength was 320 nm (HP DAD series 1100). The run time was 10 min. Quantification was performed using an external standard method. The quantitative method was validated for selectivity, reproducibility, and linearity. Samples are prepared in diluted ammonia R3 PhEur.

[0098] Step D Kolliphor HS 15 (Solutol HS 15, Ph.Eur. / USP, BASF, containing about 30% free propylene glycol), Kolliphor RH 40 (Cremophor RH 40, Ph.Eur. / USP, BASF) and TPGS-1000 (USP, Antares Health Products) (2 g) were each dissolved in 20 mL of water at about 60° C. To 10 mL of each resulting solution, 1000 mg of sulfasalazine and 735 mg of meglumine (1.5 equivalents) were added and stirred at room temperature for about 30 minutes until the sulfasalazine was completely dissolved, respectively. Stability was tested over a 2-week period when stored at room temperature in petri dishes. Purity and content were tested immediately after manufacture, after 24 hours, 48 ​​hours, 7 days, and 14 days. Sulfasalazine content was determined against a 100% sulfasalazine standard solution and purity was expressed as area % compared to the starting value.

[0099] [Table 2]

[0100] Example 3 Comparison of the transport rates of sulfasalazine and a pharmaceutical composition containing sulfasalazine of the present invention across Caco-2 cell monolayers

[0101] Caco-2 monolayer For transport experiments, Caco-2 cells were cultured at 1 cm 2 Transwell at a density of 67,800 cells per TM Cells were seeded onto filter inserts, which were placed into 12-well flat-bottom cluster plates. 0.5 mL of DMEM culture medium was placed in the inserts (apical compartment) and 1.5 mL in the outside wells (basal compartment). Cells were cultured in DMEM culture medium at 37°C, 10% CO2 and 90% relative humidity for 14-30 days until they formed a confluent monolayer. EVOM with STX-2 electrodes TMConfluency and adhesion of the cell monolayer were confirmed by measuring the transepithelial electrical resistance using a voltmeter. A TEER of 200 Ω×cm was obtained after preincubation (30 min) or after completion of the transport study. 2 If the efflux ratio was less than 0.05, the monolayer was rejected. Test items were made according to Biopharmaceutics Classification System (BCS) guidelines. Experiments were performed in triplicate. Immediately before the transport experiment, the cells were washed twice with Krebs-Ringer, after which the buffer was replaced with the transport solution. After 30 min preincubation, samples were drawn from both the donor and acceptor compartments. Six samples were taken at t = 0, 30, 60, 90, 120 and 180 min. The efflux ratio was calculated as P app (ba) / P app (ab), where P app (ba) is the apparent permeability coefficient for transport of the test compound from the basolateral to the apical side (secretory direction), P app (ab) is the apparent permeability coefficient for transport of the test compound from the apical side to the basolateral side (absorption direction). The apparent permeability coefficient P app (cm / s) was calculated as the permeability at steady state (μg / s) × (1 / initial amount of test compound in the donor compartment (μg) × 1 / area of ​​exposed cell monolayer (cm 2 ) × volume of buffer in donor compartment (cm 3 ).

[0102] Step E The enteric coating was removed from the commercially available pharmaceutical composition "Sulfasalazine medac 500 mg EC" tablets and the remaining core was crushed and dissolved in water. The aqueous solution was further diluted with KRB to the desired concentration.

[0103] Step F Sulfasalazine (1 g; 2.5 mmol) alone or sulfasalazine (1 g; 2.5 mmol) with meglumine (1.5 equiv.) were dissolved in water at room temperature under magnetic stirring until completely dissolved, and the resulting solution was further diluted with Krebs-Ringer phosphate buffer (KRB) to the desired concentration.

[0104] Step G TPGS-1000 (USP, Antares Health Products) (1 g) was dissolved in 20 mL of water at about 60° C. To the resulting solution (10 mL), 1000 mg of sulfasalazine and 735 mg of meglumine (1.5 equivalents) were added and stirred at room temperature for about 30 minutes until the sulfasalazine was completely dissolved. The aqueous solution was further diluted with KRB to the desired concentration.

[0105] [Table 3] The ba to ab ratio of the transport rate of the active pharmaceutical ingredient sulfasalazine ranges from 3.4 (2000 μg / mL) to 4.1 (200 μg / mL). The efflux ratio of a pharmaceutical composition containing 10 w / v% sulfasalazine together with 7.2 w / v% meglumine and 5 w / v% TPGS-1000 ranges from 0.5 (200 μg / mL) to 1.2 (2000 μg / mL).

[0106] Example 4 Preparation of salt crystalline forms of sulfasalazine

[0107] 4.1 Preparation of Form A Crystals of 2-Hydroxy-5-[2-[4-[(2-pyridinylamino)sulfonyl]phenyl]diazenyl]-benzoic Acid D(-)-N-Methylglucamine Salt Sulfasalazine (2.00 g, 5.0 mmol) and D(-)-N-methylglucamine (1.00 g, 5.1 mmol) were weighed into a 250 ml round bottom flask equipped with a magnetic stirrer. Acetone (200 ml) was added and the mixture was stirred at 60°C. The solid material gradually dissolved and after a few hours a new precipitate started to form. The mixture never completely dissolved. After 24 hours at 60°C, tert-butyl methyl ether (40 ml) was added through the dropping funnel (5 min) and seed (1 mg of meglumine sulfasalazine Form A salt obtained as described in Example 5) was added. After 30 min, the heat was removed and the mixture was stirred at ambient temperature for a further 60 hours. It was then filtered (Robu-Glas borosilicate glass filter porosity 3) and the solid was washed with a 20% mixture of tert-butyl methyl ether in acetone (50 ml). The material was dried in vacuum for 17 hours and weighed on the filter to give 2.92 g (97.4%) of a yellow crystalline powder which was analyzed by 1H-NMR and found to contain 0.53% w / w acetone and traces of tert-butyl methyl ether (<0.02% w / w).

[0108] 1H NMR (400 MHz, DMSO-d6) δ 8.27 (d, J = 2.7 Hz, 1H), 8.03 - 7.95 (m, 3H), 7.91 - 7.83 (m, 2H), 7.80 (dd, J = 8.9, 2.7 Hz, 1H), 7.75 (ddd, J = 8.9, 7.1, 1.9 Hz, 1H), 7.21 (d, J = 8.7 Hz, 1H), 6.86 (t, J = 6.6 Hz, 1H), 6.73 (d, J = 8.9 Hz, 1H), 5.38 (s, 1H), 4.57 (s, 1H), 4.43 (s, 1H), 3.89 - 3.80 (m, 1H), 3.66 (dd, J = 5.3, 1.6 Hz, 1H), 3.60 (dd, J = 10.8, 3.2 Hz, 1H), 3.49 (dt, J = 8.9, 4.2 Hz, 1H), 3.45 - 3.37 (m, 2H), 3.05 (dd, J = 12.6, 3.3 Hz, 1H), 2.94 (dd, J = 12.6, 9.5 Hz, 1H), 2.55 (s, 3H); 13 C NMR (101 MHz, DMSO-d6) δ 170.96, 170.29, 154.12, 141.99, 127.70, 126.94, 126.78, 122.02, 119.07, 118.24, 71.28, 70.39, 70.10, 68.34, 63.27, 50.80; loss on drying (TGA; %w / w) is 0.2; melting point (DSC) is 163.5°C ± 2.5°C (onset); water vapor uptake (GVS; %w / w) is <0.4 at 30% RH and <0.9 at 80% RH; solubility in deionized water at 24°C and pH 6.6 is >54 mg / mL; NMR confirmed a 1:1 base to acid stoichiometry.

[0109] The powder X-ray diffraction pattern of crystalline Form A of the meglumine salt of sulfasalazine shown in FIG. 1 specifically includes the following XRPD peaks (expressed in degrees 2θ±0.2°): (10) 6.35, 13.93, and 22.41, or (11) 9.31, 15.86 and 20.99, or (12) 6.35, 13.93, 15.48, 15.86, 22.41, and 23.60; or (13) 6.35, 10.79, 12.93, 13.93, 15.48, 15.86, 18.12, 19.82, and 22.41; or (14) 9.31, 10.79, 12.93, 13.93, 14.47, 15.48, 15.86, 17.56, 19.10, 23.60, and 28.07; or (15) 6.35, 12.93, 13.93, 14.47, 15.48, 15.86, 19.10, 19.82, 20.99, 21.27, 22.41, 23.60, 23.89, and 28.07; or (16) 6.35, 9.31, 10.79, 12.93, 13.93, 14.47, 15.48, 15.86, 17.78, 18.12, 19.82, 20.11, 20.99, 21.27, 22.41, 23.60, 23.89, 28.07, and 28.80; or (17) 6.35, 9.31, 10.79, 12.93, 13.93, 14.47, 15.48, 15.86, 17.56, 17.78, 18.12, 18.50, 19.10, 19.82, 20.11, 20.99, 21.27, 22.41, 23.60, 23.89, 24.70, 25.14, 25.55, 25.93, 26.81, 28.07, and 28.80; or (18) 6.35, 9.31, 10.79, 12.93, 13.93, 14.47, 15.48, 15.86, 17.56, 17.78, 18.12, 18.50, 19.10, 19.82, 20.11, 20.99, 21.27, 22.41, 23.60, 23.89, 24.70, 25.14, 25.55, 25.93, 26.81, 28.07, 28.80, 29.49, 32.01, 32.58, 33.23.

[0110] 4.2 Preparation of Form A Crystals of 2-Hydroxy-5-[2-[4-[(2-pyridinylamino)sulfonyl]phenyl]diazenyl]-benzoic Acid D(-)-N-Methylglucamine Salt To a suspension of 30 mg of sulfasalazine in acetone was added an equimolar amount of D(-)-N-methylglucamine (1 M stock solution in water). The suspension was heated to 23°C and the resulting solution was stirred for 4 days, after which the solvent was slowly evaporated. The salt product was washed, filtered and dried to give a polymorph of 2-hydroxy-5-[2-[4-[(2-pyridinylamino)sulfonyl]phenyl]diazenyl]-benzoic acid D(-)-N-methylglucamine salt designated as Form A.

[0111] 1 H-NMR (400 MHz, DMSO-d6) δ8.27 (d, J = 2.7 Hz, 1H), 8.05-7.95 (m, 3H), 7.91-7.83 (m, 2H), 7.80 (dd, J = 8.8, 2.7 Hz, 1H), 7.75 (ddd, J = 8.9, 7.2, 1.9 Hz, 1H), 7.21 (d, J = 8.7 Hz, 1H), 6.86 (t, J = 6.6 Hz, 1H), 6.73 (d, J = 8.8 Hz, 1H), 5.37 (s, 1H), 4.57 (s, 1H), 4.44 (s, 1H), 3.88-3.80 (m, 1H), 3.66 (dd, J = 5.2, 1.6 Hz, 1H), 3.60 (d, J = 10.7 Hz, 1H), 3.53-3.37 (m, 3H), 3.05 (dd, J = 12.6, 3.4 Hz, 1H), 2.94 (dd, J = 12.6, 9.5 Hz, 1H), 2.56 (s, 3H); 13 C-NMR (101 MHz, DMSO-d6) δ 171.01, 170.25, 154.13, 141.97, 127.70, 126.93, 126.78, 122.01, 119.06, 118.25, 71.28, 70.38, 70.09, 68.31, 63.26, 50.78, 40.12, 33.04; melting point (DSC): 160 °C ± 2 °C (onset); water vapor uptake (GVS; %w / w) was 0.4 at 30% RH and 1.1 at 80% RH; NMR and HPLC confirmed a 1:1 base to acid stoichiometry.

[0112] The powder X-ray diffraction pattern of crystalline Form A of the meglumine salt of sulfasalazine shown in FIG. 1 specifically includes the following XRPD peaks (expressed in degrees 2θ±0.2°): (1) 6.35, 13.93, and 22.41, or (2) 9.31, 15.86 and 20.99, or (3) 6.35, 13.93, 15.48, 15.86, 22.41, and 23.60; or (4) 6.35, 10.79, 12.93, 13.93, 15.48, 15.86, 18.12, 19.82, and 22.41; or (5) 9.31, 10.79, 12.93, 13.93, 14.47, 15.48, 15.86, 17.56, 19.10, 23.60, and 28.07; or (6) 6.35, 12.93, 13.93, 14.47, 15.48, 15.86, 19.10, 19.82, 20.99, 21.27, 22.41, 23.60, 23.89, and 28.07; or (7) 6.35, 9.31, 10.79, 12.93, 13.93, 14.47, 15.48, 15.86, 17.78, 18.12, 19.82, 20.11, 20.99, 21.27, 22.41, 23.60, 23.89, 28.07, and 28.80; or (8) 6.35, 9.31, 10.79, 12.93, 13.93, 14.47, 15.48, 15.86, 17.56, 17.78, 18.12, 18.50, 19.10, 19.82, 20.11, 20.99, 21.27, 22.41, 23.60, 23.89, 24.70, 25.14, 25.55, 25.93, 26.81, 28.07, and 28.80; or (9) 6.35, 9.31, 10.79, 12.93, 13.93, 14.47, 15.48, 15.86, 17.56, 17.78, 18.12, 18.50, 19.10, 19.82, 20.11, 20.99, 21.27, 22.41, 23.60, 23.89, 24.70, 25.14, 25.55, 25.93, 26.81, 28.07, 28.80, 29.49, 32.01, 32.58, 33.23.

[0113] 4.3 Preparation of Form A Crystals of 2-Hydroxy-5-[2-[4-[(2-pyridinylamino)sulfonyl]phenyl]diazenyl]-benzoic acid piperazine salt To a suspension of 30 mg of sulfasalazine in methanol was added an equimolar amount of piperazine (1 M stock solution in water). The suspension was heated to 23° C. and stirred for 4 days. The salt product was then filtered, washed, filtered again and dried to obtain a polymorph designated piperazine sulfasalazine Form A.

[0114] 1 H-NMR (400 MHz, DMSO-d6) δ 8.28 (d, J = 2.7 Hz, 1H), 8.00 (dt, J = 6.9, 2.1 Hz, 3H), 7.88 (d, J = 8.6 Hz, 2H), 7.84 (dd, J = 8.8, 2.7 Hz, 1H), 7.75 (ddd, J = 8.9, 7.2, 1.9 Hz, 1 H), 7.21 (d, J = 8.7 Hz, 1 H), 6.86 (t, J = 6.4 Hz, 1H), 6.79 (d, J = 8.8 Hz, 1H), 3.18 (s, 8 H); 13C-NMR (101 MHz, DMSO-d6) δ 170.55, 169.77, 154.01, 142.36, 127.71, 127.22, 126.65, 122.10, 118.49, 118.22, 41.14; melting point (DSC): 270 °C ± 2 °C (heating rate 100 K / min); water vapor uptake (GVS; %w / w) was 0.4 at 30% RH and 0.9 at 80% RH; solubility in deionized water at 24 °C after 24 h: 0.12 mg / mL; NMR and HPLC confirmed a 1:2 base to acid stoichiometry.

[0115] The powder X-ray diffraction pattern of crystalline Form A of the piperazine salt of sulfasalazine, shown in FIG. 2, specifically includes the following XRPD peaks (expressed in degrees 2θ±0.2°): (1) 11.95, 12.30 and 16.42, or (2) 12.30, 12.93 and 15.00, or (3) 11.95, 12.30, 12.93, 16.42, 17.87, and 20.36; or (4) 8.11, 11.95, 12.30, 15.01, 16.42, 17.87, 20.36, and 20.74; or (5) 11.95, 12.30, 12.93, 15.01, 16.42, 17.87, 20.36, 20.74, 22.41, and 23.41; or (6) 11.95, 15.01, 16.42, 17.87, 20.36, 20.74, 23.41, 24.01, 24.67, 24.99, and 26.09; or (7) 8.11, 11.95, 12.30, 12.93, 15.01, 16.42, 17.87, 20.36, 20.74, 22.41, 23.41, 24.01, 24.67, 24.99, and 26.09, or (8) 11.95, 12.30, 12.93, 15.01, 16.42, 17.87, 20.36, 20.74, 22.41, 23.41, 24.01, 24.67, 24.99, 26.09, 26.81, 27.73, and 28.80; or (9) 8.11, 11.95, 12.30, 12.93, 15.01, 16.42, 17.87, 20.36, 20.74, 22.41, 23.41, 24.01, 24.67, 24.99, 26.09, 26.81, 27.73, 28.80, 29.80 and 30.43.

[0116] 4.4 Preparation of Form A Crystals of 2-Hydroxy-5-[2-[4-[(2-pyridinylamino)sulfonyl]phenyl]diazenyl]-benzoic acid diethylamine salt To a suspension of 30 mg of sulfasalazine in acetonitrile was added an equimolar amount of diethylamine (1 M stock solution in water). The suspension was heated to 23° C. and stirred for 4 days. The salt product was then filtered, washed, filtered again and dried to give a polymorph designated diethylamine sulfasalazine Form A.

[0117] 1 H-NMR (400 MHz, DMSO-d6) δ 8.26 (d, J = 2.7 Hz, 1H), 8.02-7.95 (m, 3H), 7.87 (d, J = 8.3 Hz, 2H), 7.79 (dd, J = 8.9, 2.7 Hz, 1H), 7.75 (t, J = 8.7, 7.6 Hz, 1 H), 7.21 (d, J = 8.6 Hz, 1 H), 6.86 (s, 1H), 6.72 (d, J = 8.8 Hz, 1H), 2.93 (q, J = 7.3 Hz, 4 H), 1.16 (t, J = 7.3 Hz, 6 H); 13 C-NMR (101 MHz, DMSO-d6) δ 170.21, 141.91, 126.91, 126.79, 121.99, 119.06, 118.27, 41.35, 11.05; melting point (DSC): 200 °C ± 2 °C (heating rate 10 K / min); water vapor uptake (GVS; %w / w) was 0.3 at 30% RH and 0.5 at 80% RH; solubility in deionized water at 24 °C after 24 h: >0.31 mg / mL; NMR and HPLC confirmed a 1:1 base to acid stoichiometry.

[0118] The powder X-ray diffraction pattern of crystalline Form A of the diethylamine salt of sulfasalazine, shown in FIG. 3, specifically includes the following XRPD peaks (expressed in degrees 2θ±0.2°): (1) 7.16, 11.48, and 18.78, or (2) 10.50, 15.41, and 21.87; or (3) 7.16, 10.50, 11.48, 18.78, 21.65, and 21.87; or (4) 10.50, 11.48, 12.42, 14.38, 15.41, 16.64, 18.78, and 21.87; or (5) 7.16, 10.50, 11.01, 11.48, 13.87, 15.92, 16.64, 18.78, 21.08, 21.65, and 22.15; or (6) 7.16, 10.50, 11.01, 11.48, 12.42, 13.87, 14.38, 15.41, 15.92, 16.64, 17.19, 18.28, 18.78, 21.08, 21.65, 21.87, and 22.15; or (7) 7.16, 10.50, 11.48, 12.42, 13.87, 14.38, 15.41, 15.92, 16.64, 20.52, 21.08, 21.65, 21.87, 22.15, 22.47, 23.16, 23.63, 24.14, and 25.11, or (8) 7.16, 10.50, 11.01, 11.48, 12.42, 13.87, 14.38, 15.41, 15.92, 16.64, 17.19, 18.28, 18.78, 20.52, 21.08, 21.65, 21.87, 22.15, 22.47, 23.16, 23.63, 24.14, and 25.11, or (9) 7.16, 10.50, 11.01, 11.48, 12.42, 13.87, 14.38, 15.41, 15.92, 16.64, 17.19, 18.28, 18.78, 20.52, 21.08, 21.65, 21.87, 22.15, 22.47, 23.16, 23.63, 24.14, 25.11, 26.94, 27.95, 28.92, 29.46.

[0119] 4.5 Diethylamine Preparation of Form B Crystals of 2-hydroxy-5-[2-[4-[(2-pyridinylamino)sulfonyl]phenyl]diazenyl]-benzoic acid diethylamine salt 25 mg of sulfasalazine was added to 5 ml of acetone and a solution containing 10% excess of the counterion diethylamine in acetone was added. The mixture was heated to 45° C. and the solvent was slowly evaporated to give a polymorph designated diethylamine sulfasalazine salt Form B.

[0120] The powder X-ray diffraction pattern of crystalline Form B of the diethylamine salt of sulfasalazine, shown in FIG. 4, specifically includes the following XRPD peaks (expressed in degrees 2θ±0.2°): (1) 6.85, 17.82, and 22.75, or (2) 11.38, 20.58, and 23.98, or (3) 6.85, 11.38, 17.82, 20.58, and 22.75; or (4) 6.85, 11.38, 11.70, 17.62, 20.58, 22.75, and 23.98; or (5) 11.38, 11.70, 15.29, 16.71, 17.62, 19.92, 20.58, 21.30, 22.75, 23.63, and 23.98; or (6) 6.85, 11.38, 11.70, 14.78, 15.29, 15.70, 16.71, 17.62, 19.92, 20.20, 20.58, 21.30, 22.75, 23.63, 23.98, and 28.61; or (7) 6.85, 11.38, 11.70, 14.78, 15.29, 15.70, 16.71, 17.62, 19.92, 20.20, 20.58, 21.30, 22.75, 23.63, 23.98, 25.05, 25.71, 26.81, 27.95, and 28.61; or (8) 6.85、11.38、11.70、14.78、15.29、15.70、16.71、17.62、19.92、20.20、20.58、21.30、22.75、23.63、23.98、25.05、25.71、26.81、27.95、28.61、29.14、31.06。

Claims

1. 1. A pharmaceutical composition for oral administration comprising: i) a core material; and ii) an enteric coating material applied as a layer on the core material, wherein i) the core material comprises the following components: a) a therapeutically effective amount of 2-hydroxy-5-[2-[4-[(2-pyridinylamino)sulfonyl]phenyl]diazenyl]-benzoic acid (sulfasalazine) and / or an organic salt of sulfasalazine, and b) an organic amine-containing component selected from meglumine, piperazine, and diethylamine, and c) one or more further pharmaceutical excipients 13. A pharmaceutical composition comprising:

2. 2. The pharmaceutical composition according to claim 1, wherein i) the core material comprises a therapeutically effective amount of 2-hydroxy-5-[2-[4-[(2-pyridinylamino)sulfonyl]phenyl]diazenyl]-benzoic acid (sulfasalazine) and / or a sulfasalazine organic salt as component a) and an organic amine-containing component selected from meglumine, piperazine and diethylamine as component b) an excipient thereon as pharmaceutical additive as component c).

3. 3. The pharmaceutical composition of claim 2, wherein the excipient is selected from the group consisting of a water-insoluble oxidized substance, a water-insoluble cellulose substance, a water-insoluble organic polymeric substance or a mixture thereof, and / or a water-soluble inorganic salt substance, a water-soluble sugar substance, a water-soluble starch substance or a mixture thereof.

4. 4. The pharmaceutical composition of claim 3, wherein the formulation of the pharmaceutical composition for oral administration is selected from a solid pharmaceutical composition or a liquid pharmaceutical composition.

5. - the formulation of the solid pharmaceutical composition is further selected from the group consisting of granules, multi-unit pellet systems (MUPS), tablets, multi-unit pellet tablets (MUP tablets), capsules and powders; or - the formulation of the liquid pharmaceutical composition is further selected from the group consisting of syrups and suspensions; 5. The pharmaceutical composition according to claim 4.

6. 6. The pharmaceutical composition of claim 5, wherein the capsule is formulated as a soft gelatin capsule containing one or more further pharmaceutical excipients selected from the group consisting of surfactants / solubilizers, vegetable oils and / or polyethylene glycol.

7. 6. The pharmaceutical composition of claim 5, wherein the capsule is formulated as a hard gelatin capsule containing one or more additional pharmaceutical excipients selected from the group consisting of surfactants / solubilizers.

8. 6. The pharmaceutical composition according to any one of claims 1 to 5, wherein i) the core material comprises a plurality of compressed core materials compressed to form a compressed tablet core, each of the plurality of compressed core materials being respectively coated with one or more separating layers forming the compressed tablet core, and the compressed tablet core being coated with an enteric coating layer.

9. The pharmaceutical composition according to any one of claims 1 to 8, wherein the enteric coating of the pharmaceutical composition for oral administration is further coated with an overcoating layer.

10. The pharmaceutical composition according to any one of claims 1 to 9, wherein the thickness of the enteric coating layer is at least 5 μm.

11. i) a human disease or condition in which modulation of inflammatory cells is beneficial; ii) a disease or condition involving the bones or joints, and iii) Diseases or conditions related to the gastrointestinal tract A pharmaceutical composition according to any one of claims 1 to 10 for the treatment of

12. 12. The pharmaceutical composition of claim 11, wherein the disease or condition relating to bones or joints is selected from the group of rheumatoid arthritis, juvenile arthritis including idiopathic inflammatory arthritis of any joint position and associated syndromes, and seronegative spondyloarthropathy including ankylosing spondylitis.

13. 13. A pharmaceutical composition according to any one of claims 1 to 12 for use in sequential or parallel co-administration with one or more further pharmaceutical compositions.

Citation Information

Patent Citations

  • Purifying process for salazosulfapyridine

    CN106279008A

  • JP1974024650A